decision,explanation
True,"<This study meets all the inclusion criteria, including the diagnosis of treatment-resistant schizophrenia, the use of olanzapine and haloperidol as interventions, and the measurement of effectiveness outcomes such as symptom response and hospitalization.>"
False," The study population in this paper does not match the inclusion criteria as it only includes adults (18 years and older) with schizophrenia, whereas the review includes a broader age range (13-17 years) and diagnoses (e.g., bipolar disorder, major depressive disorder)."
True," The study meets all the inclusion criteria, including the population (patients with Parkinson's disease and drug-induced psychosis), intervention (low-dose clozapine), and outcomes (improvement in psychosis severity and parkinsonism symptoms)."
False," The article does not match the specified population of interest, which includes patients with Parkinson's disease, whereas the article is about managing psychosis in patients with Parkinson's disease."
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia, whereas the review includes children, adolescents, and adults with various psychiatric conditions."
True," The study meets all the inclusion criteria, including the population (schizophrenic patients), intervention (errorless learning approach), and study design (randomized controlled trial)."
True," The study meets the inclusion criteria as it examines the predictors of relapse in patients with first-episode schizophrenia or schizoaffective disorder, which is a relevant population for this review."
False," The study population (patients with dementia) does not match the inclusion criteria, which specifies adults (age 18 years and older) with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
False," The study population does not meet the inclusion criteria as it only includes adults and children with schizophrenia, whereas the review focuses on adults with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The study population does not match the specified population for this review, as it focuses on patients with chronic schizophrenia, whereas the review includes a broader range of patient populations."
False," The title and abstract suggest that the paper is a review of the costs of schizophrenia, but the inclusion criteria specify a wide range of psychiatric conditions and interventions, whereas the title and abstract only mention schizophrenia."
False," The article does not meet the inclusion criteria as it is a review of quality of life in patients with schizophrenia, and does not discuss the effectiveness or harms of a specific medication."
False," The study is not a randomized controlled trial, but rather a cohort pilot study, which does not meet the inclusion criteria."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of ziprasidone in treating acute exacerbation of schizophrenia and schizoaffective disorder, and includes outcomes such as symptom response, adverse events, and discontinuation."
True," The study meets the inclusion criteria as it is a randomized controlled trial (RCT) evaluating the efficacy and safety of amisulpride in patients with schizophrenia, which is a relevant population for this review."
False," The article's topic, sudden infant death syndrome, child sexual abuse, and child development, does not match the specified inclusion criteria, which focus on psychiatric disorders and medications in adults, adolescents, and children with specific diagnoses."
True," The study meets all the inclusion criteria, including a randomized controlled trial design, a comparison of olanzapine with haloperidol, and an examination of effectiveness outcomes in schizoaffective disorder."
True," The study meets all the inclusion criteria as it is a randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol, and it includes effectiveness outcomes such as the risk of tardive dyskinesia."
False," The study population is premenopausal women treated with risperidone, which does not match the inclusion criteria of adults and adolescents with various psychiatric disorders, and the study design is not mentioned in the abstract."
False, The study does not meet the inclusion criteria as it does not investigate the effectiveness or harms of the specified interventions (atypical antipsychotic drugs) in the specified patient populations.
False," The study does not focus on a specific population or condition, but rather aims to critically appraise methodological flaws in clinical trials of new antipsychotics across various patient populations."
True, The study meets the inclusion criteria as it involves individuals with schizophrenia and compares their BMI distribution to that of individuals without schizophrenia.
False," The title and abstract do not indicate that the study focuses on psychotropic drugs in mothers' milk, but rather provides a comprehensive review of psychotropic drugs in general."
True," The study meets all inclusion criteria, including a randomized controlled trial design, a comparison of clozapine with typical neuroleptics, and an examination of cognitive function in neuroleptic-responsive schizophrenia."
True," The study meets all the inclusion criteria, including the population (male schizophrenics treated with clozapine), interventions (clozapine), and outcomes (MEG activity)."
True," The study meets the inclusion criteria as it involves elderly patients with psychotic disorders, specifically schizophrenia or schizoaffective disorder, and evaluates the safety, tolerability, and efficacy of risperidone."
True," The study meets the inclusion criteria as it is a randomized controlled trial (RCT) examining the efficacy of olanzapine versus placebo in the treatment of acute mania, which is within the specified intervention and population of interest."
False,"<This study does not meet the inclusion criteria as it only examines the relationship between weight gain and treatment response to clozapine among male and female patients with schizophrenia, and does not evaluate the effectiveness or harms of clozapine in any of the specified patient populations.>"
True," The study meets the inclusion criteria as it is a randomized, double-blind, crossover study examining the acute and chronic effects of clozapine in patients with essential tremor."
False," The study's population is limited to treatment-refractory schizophrenic patients treated with clozapine, which does not match the inclusion criteria of adults with schizophrenia, including treatment-resistant patients."
False," The study population of interest is older adults (≥ 65 years of age) with bipolar disorder, but the review paper is focused on schizophrenia, bipolar disorder, and other psychiatric conditions in various age groups."
True," The study includes patients with schizophrenia and schizoaffective disorder treated with high doses of olanzapine, which matches the inclusion criteria."
False," The study population in this article does not match the inclusion criteria, as it only includes adults and adolescents with bipolar disorder, whereas the inclusion criteria specify a broad range of populations, including schizophrenia, major depressive disorder, and behavioral and psychological symptoms of dementia."
True," The study meets the inclusion criteria as it examines the cost-effectiveness of clozapine in patients with refractory schizophrenia, which is a relevant population for this review, and uses a randomized controlled trial design to compare clozapine with haloperidol."
True," The study meets all the inclusion criteria, including the population (patients discharged from state psychiatric facilities), interventions (risperidone and clozapine), and outcomes (rehospitalization rates)."
True," The study includes adults with schizophrenia, bipolar disorder, and major depressive disorder, which are all relevant to the review's inclusion criteria."
True,"<This study meets the inclusion criteria as it is a randomized controlled trial comparing the incidence of tardive dyskinesia between risperidone and haloperidol in older patients, which is a relevant population for this review, and it reports on effectiveness outcomes such as symptom response and hospitalization, and harms outcomes such as overall adverse effects and withdrawals due to adverse events.>"
False," The study population is limited to chronic psychiatric inpatients with schizophrenia, which does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The article's population of interest is adults and adolescents with schizophrenia, bipolar disorder, and other disorders, which does not match the specified inclusion criteria."
True," The study meets the inclusion criteria for patients with schizophrenia, as it examines the effects of clozapine on cognitive functioning in individuals with schizophrenia."
False," The study does not meet the inclusion criteria for the review as it is not a randomized controlled effectiveness trial, but rather a pharmacological experiment examining the effect of risperidone on plasma norepinephrine levels."
False," The study population specified in the inclusion criteria does not match the title, which focuses on drug-induced psychosis in Parkinson's disease."
False," The study does not meet the inclusion criteria as it is a pharmacokinetic study examining the interaction between erythromycin and clozapine, and does not report on the effectiveness or harms of clozapine in any of the specified patient populations."
True," The study meets all the inclusion criteria, including the diagnosis of treatment-resistant schizophrenia, the use of clozapine and olanzapine as interventions, and the measurement of effectiveness outcomes such as symptom response and adherence."
False," The study does not meet the inclusion criteria as it is a single study examining the sleep-promoting effects of olanzapine in schizophrenic patients, whereas the review focuses on randomized controlled trials, systematic reviews, and comparative observational studies examining the effectiveness and harms of various antipsychotic medications in different patient populations."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of risperidone as an intervention, and the assessment of effectiveness outcomes such as symptom response and functional capacity."
True," The review meets all the inclusion criteria, including the population (adults and adolescents with schizophrenia), interventions (clozapine), and outcomes (clinical improvement, relapse prevention, acceptability of treatment)."
True," The article meets all the inclusion criteria, including the population (adults and adolescents with various psychiatric disorders), interventions (risperidone and clozapine), and outcomes (effectiveness and harms) of interest."
True," The study meets the inclusion criteria as it examines the effectiveness of novel antipsychotics in adults with schizophrenia, and it meets the criteria for study design as it is a retrospective analysis."
False," The study population does not meet the inclusion criteria, as it specifically focuses on patients with recent-onset schizophrenia and other psychotic disorders, whereas the review paper includes a broader range of patient populations, such as bipolar disorder, major depressive disorder, and pervasive developmental disorders."
False," The study population is limited to outpatients with schizophrenia who have failed to respond to antipsychotic medication, which does not meet the inclusion criteria for patients with schizophrenia, including those with a first episode and treatment resistance."
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial design, and examines the effectiveness of cognitive-behavioral therapy plus social skills training in conjunction with clozapine."
False," The study population does not match the inclusion criteria, as it only includes adults with mania, whereas the review includes a wide range of psychiatric disorders and age groups."
False," The study is in adolescents with acute mania, but the inclusion criteria specify adults and adolescents with schizophrenia, bipolar disorder, or major depressive disorder, and the study population does not meet the specified age range for bipolar disorder."
True," The study meets all inclusion criteria, including a focus on atypical antipsychotic drugs, a meta-analysis of randomized, placebo-controlled trials, and a comparison of olanzapine, quetiapine, and risperidone."
False," The article does not meet the inclusion criteria as it is a review and meta-analysis of the effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia, but it does not specify that it is focused on adults (age 18 years and older) with schizophrenia."
True," The study meets all the inclusion criteria, including the population of interest (treatment-resistant schizophrenia patients), the intervention (risperidone vs. haloperidol), the outcome (secondary memory), and the study design (randomized controlled trial)."
True," The study meets all inclusion criteria, including a focus on adults and adolescents with schizophrenia, a specific review of the effects of clozapine, olanzapine, and risperidone on cognition, and inclusion of relevant outcomes such as cognitive function and symptom response."
False," The study population does not match the specified inclusion criteria, as it only includes adults and adolescents with schizophrenia, whereas the review paper includes a broader range of patient populations."
True," The study meets all the inclusion criteria, as it involves patients with schizophrenia, uses a randomized controlled trial design, and examines the effect of glucose on memory performance."
False," The abstract does not mention a specific population of interest, such as adults with schizophrenia, but rather describes a workshop on antipsychotic medications."
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in patients with schizophrenia, and it uses the SF-36 to measure perceived functioning and well-being."
False," The study population does not match the specified inclusion criteria, as it only includes adults and adolescents with schizophrenia or schizoaffective disorder, whereas the review includes a broader range of psychiatric disorders and age groups."
False," The study population does not match the inclusion criteria, as the study focuses on chronic schizophrenic patients with prominent negative symptoms, whereas the review includes patients with a wide range of psychiatric conditions, including schizophrenia with different symptom profiles."
True," The study meets all inclusion criteria, as it involves adults and adolescents with schizophrenia, examines the effectiveness of olanzapine, and includes outcomes such as quality of life and hospitalization."
False," The study does not meet the inclusion criteria as it does not involve the specified patient populations (schizophrenia, bipolar disorder, etc.) and does not examine the specified outcomes (mortality, quality of life, etc.)."
False," The study population does not match the inclusion criteria, as it only includes adults with cannabis-induced psychotic disorder, whereas the review is focused on a broader range of psychiatric conditions, including schizophrenia, bipolar disorder, and others."
False," The study population does not include children under 13 years old with pervasive developmental disorders or disruptive behavior disorders, which is one of the specified inclusion criteria."
True," The study meets all the inclusion criteria, including a randomized controlled trial design, a focus on schizophrenia, and an evaluation of the effectiveness of a specific intervention (mianserin) on a specific outcome (neuroleptic-induced akathisia)."
True," The study meets all inclusion criteria, including the population (patients with treatment-resistant illness and a history of mania), interventions (clozapine add-on therapy and treatment as usual), outcomes (clinical improvement, mood-stabilizing property), and study design (randomized controlled trial)."
False," The study population does not match the inclusion criteria as it only includes adults with borderline personality disorder and psychoses, whereas the review paper includes a broader range of populations such as schizophrenia, bipolar disorder, and dementia."
True," The study meets all inclusion criteria, including the population of interest (patients with schizophrenia), intervention (quetiapine fumarate), and study design (randomized controlled trial)."
False," The article is about the safety profile of amisulpride, but it does not meet the inclusion criteria as it is not a randomized controlled trial, nor is it a systematic review or observational study examining the relationship between improved adherence or persistence and improved outcomes."
True," The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in treating schizophrenia and other psychotic disorders, with outcomes including quality of life and clinical symptoms."
False," The study population does not match the inclusion criteria as it specifically mentions adults and adolescents with a diagnosis of schizophrenia, bipolar disorder, and other conditions, but the age range of 18-17 years is not specified."
False," The study population is elderly patients with psychosis, which does not match the specified inclusion criteria for the review, which focuses on patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia in adults aged 18 and older, and other specific populations."
True," The study meets all the inclusion criteria, including the population (schizophrenic patients), interventions (clozapine), and outcomes (awareness of illness and cognition)."
True," The study meets all the inclusion criteria, including the diagnosis of treatment-refractory schizophrenia, the intervention of risperidone, and the outcomes of clinical efficacy and tolerability."
True," The study meets all the inclusion criteria, including the population (hospitalized manic-depressive patients), the focus on diabetes mellitus, and the study design (randomized controlled trial)."
False," The study population is patients with obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors, which does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
False," The article does not meet the inclusion criteria because it does not report on the effectiveness of the specified interventions for the specified patient populations, and the study design and outcomes do not match the specified criteria."
False," The study only examines the clinical efficacy of olanzapine in Japan, whereas the review paper appears to be interested in a broader population and geographic region."
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of risperidone in treating behavioral symptoms of dementia in older adults.
True,"<This study meets the inclusion criteria as it involves adults with treatment-resistant schizophrenia, a relevant population for the review, and reports on the effectiveness of olanzapine, a medication included in the review. The study also reports on outcomes of interest such as symptom response, functional capacity, and adverse effects.>"
False," The study population and interventions do not match the inclusion criteria, as the study focuses on the addition of fluvoxamine to clozapine in schizophrenia, but the review paper only includes studies on a specific list of medications (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone)."
False," The study does not meet the inclusion criteria for patient population, as it only includes adults with schizophrenia who are discontinuing clozapine, whereas the review includes a broader range of patient populations and age groups."
False," The article does not meet the inclusion criteria as it is about psychopharmacology in autism, but the review paper's focus is on adults and adolescents with schizophrenia, bipolar disorder, and other conditions, not autism."
False, The article does not report on the effectiveness or harms of olanzapine in any of the specified patient populations or outcomes.
False," The study does not focus on the effectiveness or harms of the medications listed, but rather on the brain metabolic patterns of patients with schizophrenia treated with clozapine and fluphenazine."
True," The study meets the inclusion criteria for the population (bipolar I disorder), intervention (lithium and carbamazepine), and outcome (prophylactic efficacy) of interest."
False," The article does not meet the inclusion criteria as it is about the diagnosis and management of Alzheimer's disease, which is not within the specified topic of schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, or disruptive behavior disorders."
True, The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the effectiveness and costs of olanzapine and haloperidol for the treatment of schizophrenia.
True," The study meets all the inclusion criteria, including being a randomized controlled trial comparing olanzapine with haloperidol in the treatment of schizophrenia, and reporting on effectiveness and economic outcomes."
True," The study meets all the inclusion criteria, including being a head-to-head randomized controlled trial comparing the effectiveness of two atypical antipsychotics, risperidone and olanzapine, in the treatment of schizophrenia."
False," The article is about rapid-cycling bipolar disorder, which is not within the specified inclusion criteria of the review paper, which focuses on adults with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, as well as children and adolescents with pervasive developmental disorders and disruptive behavior disorders."
True," The study meets all the inclusion criteria, including the focus on antipsychotic-induced weight gain, the inclusion of adults and adolescents with various psychiatric disorders, and the examination of multiple effectiveness and harm outcomes."
True," The study meets the inclusion criteria as it is a randomized controlled trial (RCT) examining the effectiveness of clozapine in patients with treatment-refractory schizophrenia, which is a population of interest for this review."
True," The study meets all the inclusion criteria, including a randomized controlled trial design, a focus on schizophrenia, and an assessment of the effectiveness of adding D-serine to clozapine."
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effects of risperidone on frontal cortical activation in patients with schizophrenia, which is a relevant population for the review."
False," The article does not meet the inclusion criteria as it is a review of the pharmacological effects of sigma-receptor ligands, not a randomized controlled effectiveness trial or a systematic review of the specified interventions and patient populations."
False," The study population specified in the abstract does not match the inclusion criteria, which are focused on adults (18+ years), adolescents (13-17 years), and children (under 13 years) with various psychiatric conditions, whereas the title and abstract suggest the study is focused on older adults (≥ 65 years) with Alzheimer's dementia."
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with mania, whereas the review includes a broader range of patient populations."
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, systematic review, or comparative observational study examining the effectiveness of a specific intervention in a relevant population."
True," The study meets all inclusion criteria, including the population of interest (adults with schizophrenia), interventions (antipsychotic medications), and outcomes (retention rates, psychopathology at screening), and the study design (retrospective study of clinical trials)."
True," The study meets all inclusion criteria, including the population (schizophrenia-spectrum patients), intervention (risperidone), and outcomes (hospitalization)."
False," The study population (physically healthy young adults with schizophrenia) does not match the inclusion criteria (schizophrenia in adults, adolescents, and children, as well as other disorders such as bipolar disorder, major depressive disorder, and dementia)."
False, The study does not meet the inclusion criteria because it focuses on a specific medication (olanzapine) and does not examine the effectiveness or harms of the included interventions for the specified patient populations.
False," The study population (patients with neuroleptic-induced akathisia) does not match the specified inclusion criteria for the review (schizophrenia, bipolar disorder, major depressive disorder, etc.)."
False," The article does not meet the inclusion criteria as it is a pharmacokinetic analysis of a specific drug interaction, whereas the review paper is focused on the effectiveness and harms of specific medications for various psychiatric and neurological disorders."
False," The study does not meet the inclusion criteria as it does not involve any of the specified patient populations (e.g. schizophrenia, bipolar disorder, etc.) and does not examine the effectiveness or harms of the specified interventions (e.g. aripiprazole, clozapine, etc.)."
True,"<The study investigates the relationship between CYP2D6 mutations and schizophrenia, and examines the clinical outcomes in schizophrenic patients with different CYP2D6 genotypes, which aligns with the inclusion criteria of the review paper.>"
True," The study meets all the inclusion criteria, including the population (schizophrenia patients), interventions (no specific intervention mentioned, but the study is a naturalistic observation), and outcomes (brain event-related potentials, accuracy of word recognition memory)."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia, the use of the recurring digit span memory test, and the inclusion of control subjects and siblings of patients."
True, The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the effectiveness of amisulpride and risperidone in patients with acute exacerbations of schizophrenia.
True," The study meets all the inclusion criteria as it involves adults with a diagnosis of schizophrenia, examines the relationship between parkinsonism and cognitive impairment, and reports on the prevalence and correlates of parkinsonism in a cohort of institutionalized geriatric patients with chronic schizophrenia."
False," The article does not match the specified inclusion criteria as it discusses dementia in developing countries, which is not within the scope of the specified inclusion criteria."
False," The study does not meet the inclusion criteria as it does not focus on the specified patient populations (e.g. adults with schizophrenia, bipolar disorder, etc.) or interventions (e.g. aripiprazole, clozapine, etc.)."
True," The study meets all the inclusion criteria, including the population of interest (schizophrenia patients), interventions (antipsychotics), and outcomes (neuropsychological test performance)."
False," The study population does not match the inclusion criteria, as the study focuses on psychiatric patients being treated with mirtazapine and risperidone, but the inclusion criteria specify patients with schizophrenia, bipolar disorder, major depressive disorder, and other specific conditions."
False," The study population is not limited to adults (18 years and older) with schizophrenia, but also includes adolescents (13-17 years) and patients with other disorders such as bipolar disorder and major depressive disorder."
True," The study population, interventions, and outcomes of interest in the article match the specified criteria for inclusion."
True," The study meets all the inclusion criteria, including the diagnosis of refractory schizophrenia, the use of clozapine as an intervention, and the inclusion of effectiveness outcomes such as symptom response and quality of life."
True," The study meets all inclusion criteria, including the population (first-episode psychotic patients), interventions (risperidone and haloperidol), and outcomes (clinical improvement, tolerability, and efficacy)."
True," The study meets all the inclusion criteria, including the population of interest (adults and adolescents with schizophrenia, bipolar disorder, and other disorders), interventions (atypical antipsychotic agents), outcomes (effectiveness and harms), and study design (randomized controlled trials, good quality systematic reviews, and comparative observational studies)."
True," The study meets the inclusion criteria as it involves a combination of electroconvulsive therapy (ECT) and clozapine, which is one of the interventions included in the review, and it examines the effectiveness and safety of this combination treatment in patients with treatment-resistant psychiatric conditions."
False," The study population consists of young patients with first-episode schizophrenia, which does not match the inclusion criteria of adults and adolescents with schizophrenia, including first-episode schizophrenia."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of atypical neuroleptics (risperidone and haloperidol), and the focus on sustained attention deficits."
True," The article meets the inclusion criteria as it is a study on clozapine, a medication included in the review, and examines its effectiveness and safety in patients with schizophrenia and other psychiatric disorders."
False, The study does not meet the inclusion criteria because it does not involve any of the interventions or patient populations specified in the review.
True," The study meets all the inclusion criteria, including the population (psychotic women), intervention (investigation of neuroleptic side effects), and study design (randomized cross-over design), and addresses the topic of extrapyramidal symptoms and oestrogen."
False," The study population of the abstract does not match the inclusion criteria, as it specifically includes only patients with schizophrenia who are resistant to treatment with typical neuroleptics, whereas the inclusion criteria include a broader range of populations, including patients with bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False, The study population specified in the inclusion criteria (adults with unipolar depression) does not match the study population described in the abstract (young patients with unipolar depression).
False," The study population does not match the inclusion criteria as it is focused on treatment-resistant bipolar disorder, whereas the review is focused on schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
True,"<The study meets all the inclusion criteria, including the population (adults with schizophrenia), interventions (olanzapine, risperidone, and haloperidol), and outcomes (cognitive benefits)."
True," The study meets all the inclusion criteria, including a randomized controlled trial design, a comparison of quetiapine with a conventional antipsychotic (haloperidol), and an examination of efficacy and tolerability outcomes."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the type of intervention (psychoeducational multiple-family group treatment), and the outcome measure (reduced negative symptoms)."
True," The study meets the inclusion criteria of investigating the relationship between D2 receptor occupancy and clinical response, side effects, and hyperprolactinemia in patients with first-episode schizophrenia, using a double-blind PET study design."
False," The study population is not specified as adults (18+ years) with schizophrenia, but rather male schizophrenic subjects (both inpatients and outpatients), which does not meet the specified inclusion criteria."
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of eicosapentaenoic acid in treating schizophrenia, with outcomes including symptom remission, normalization of blood fatty acids, and structural brain changes."
False," The article does not focus on the specified patient populations, including adults with major depressive disorder, older adults with behavioral and psychological symptoms of dementia, children with pervasive developmental disorders, and adolescents with disruptive behavior disorders."
False," The study focuses on the methodology of randomized clozapine trials, but does not examine the effectiveness or harms of clozapine in a specific patient population."
False," The abstract does not mention any specific interventions or populations that match the inclusion criteria, and it appears to be a general overview of pharmacogenetics in psychiatric treatment rather than a review of specific studies."
False," The study population is not limited to adults (age 18 years and older) and adolescents (age 13 to 17 years) with a DSM III-R or DSM-IV diagnosis of schizophrenia, but also includes patients with other psychiatric conditions."
False," The study population is limited to patients with bipolar disorder, which does not match the inclusion criteria that specify a wide range of psychiatric and neurological disorders."
False," The study population is veterans with treatment-refractory schizophrenia, which does not meet the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, and other specified disorders."
True," The study meets all inclusion criteria, including the population (adults with schizophrenia), interventions (glycine added to clozapine), outcomes (positive and negative symptoms, cognitive function), and study design (randomized controlled trial)."
False," The study population is not limited to adults (18 years and older) and adolescents (13-17 years) with a specific diagnosis, but also includes older adults (≥ 65 years of age) and children (under 13 years) with different diagnoses."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia or schizoaffective disorder, the use of atypical antipsychotics, and the examination of effectiveness and harms outcomes."
False," The study population does not match the criteria as it includes women with depressed mood during pregnancy and postpartum, whereas the review is focused on individuals with specific psychiatric diagnoses such as schizophrenia, bipolar disorder, and major depressive disorder."
False," The study does not meet the inclusion criteria because it is a naturalistic study examining the impact of switching from standard neuroleptics to atypical antipsychotics in an intensive psychiatric care unit, which is not a randomized controlled trial, comparative observational study, or systematic review."
False," The study does not focus on the effectiveness of risperidone, but rather on the relationship between Gilbert's syndrome and schizophrenia."
True," The study meets all the inclusion criteria, including the population (adults with chronic schizophrenia), interventions (risperidone vs. conventional neuroleptics), and outcomes (efficacy as measured by symptom response, adherence, and persistence)."
False," The study does not meet the inclusion criteria as it is not a randomized controlled effectiveness trial, but rather a randomized, double-blind trial examining the effectiveness of risperidone for the treatment of cocaine dependence."
False," The study is not a randomized controlled trial, but rather a preliminary investigation and a review of hospital records."
False," The study population only includes adults and adolescents with schizophrenia, bipolar disorder, and other conditions, which does not meet the inclusion criteria of the review, which also includes children with pervasive developmental disorders and disruptive behavior disorders."
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of amisulpride in adults with schizophrenia.
False," The study does not examine the effectiveness or harms of any interventions, and it does not meet the criteria for inclusion in the review of randomized controlled trials, systematic reviews, and observational studies examining the effectiveness or harms of interventions for schizophrenia."
False," The study population does not match the inclusion criteria as it only includes adults with schizophrenia, whereas the inclusion criteria specify a broader range of patient populations, including adolescents and children with various diagnoses."
False," The study does not focus on the effectiveness of atypical neuroleptics in treating negative symptoms in adult patients with schizophrenia, but rather discusses the results of controlled studies in acute schizophrenic patients and mentions the need for further studies in chronic schizophrenic patients."
True,"<The study meets all the inclusion criteria, including the population (psychotic patients with schizophrenia, schizoaffective disorder, or bipolar disorder), interventions (clozapine), and outcomes (effectiveness and harms) of interest, and is a randomized controlled trial, which is a high level of evidence included in the review.>"
True," The study meets the inclusion criteria as it includes adults with schizophrenia, a diagnosis of interest in this review, and evaluates the safety and effectiveness of olanzapine compared to other antipsychotic drugs."
True," The study meets all the inclusion criteria, including the population (patients with schizophrenia), intervention (clozapine vs. haloperidol), outcomes (medication continuation and compliance), and study design (randomized controlled trial)."
True, The study meets the inclusion criteria as it compares the effects of two antipsychotic medications (clozapine and olanzapine) on EEG patterns in patients with schizophrenia.
False," The study population is not limited to adults (age 18 years and older) with schizophrenia, but also includes adolescents (age 13-17 years) and patients with other conditions such as bipolar disorder, major depressive disorder, and dementia."
True," The study meets all the inclusion criteria as it involves elderly patients (≥ 65 years of age) with psychosis, examines the effectiveness of risperidone, and reports on outcomes such as symptom response, adherence, and persistence."
False," The article is about a method for determining the levels of risperidone and its metabolite in plasma, but it does not mention any of the specified patient populations or outcomes of interest."
False," The study population of the paper (patients with atypical antipsychotics-related weight gain) does not match the inclusion criteria (schizophrenia, bipolar disorder, major depressive disorder, etc.)."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia, the comparison of quetiapine with haloperidol, and the evaluation of effectiveness and harms."
False," The study population does not match the inclusion criteria, as the study focuses on elderly patients with dementia, whereas the inclusion criteria specify schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia in older adults (≥ 65 years of age), but not dementia specifically."
False," The study population specified in the abstract does not match the inclusion criteria, as the abstract mentions a review of clozapine augmentation in patients with refractory schizophrenia, bipolar disorder, and other conditions, but does not specifically mention the age ranges and diagnoses specified in the inclusion criteria."
True," The study meets all inclusion criteria, including the population (patients with schizophrenia or schizoaffective disorder and co-occurring substance use disorder), interventions (clozapine), and outcomes (reductions in severity of alcohol abuse and days of alcohol use)."
True," The study meets all the inclusion criteria as it involves adults with a diagnosis of schizophrenia treated with clozapine, and it examines the electrocardiographic abnormalities as an outcome of interest."
False," The study population specified in the inclusion criteria does not match the population described in the abstract, which focuses on individuals with autistic disorder and other pervasive developmental disorders, rather than adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and dementia."
False," The study does not examine the effectiveness of the medication in the specified patient populations (schizophrenia, bipolar disorder, etc.) and instead focuses on a single case report of a patient with schizophrenia who experienced weight gain while taking olanzapine."
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia and bipolar disorder, and examines the effectiveness of olanzapine and sertindole."
False," The study population is adults with developmental stuttering, which does not match the inclusion criteria of adults (age 18 years and older) with a DSM III-R or DSM-IV diagnosis of schizophrenia, bipolar disorder, major depressive disorder, or other specified disorders."
False," The study population does not match the inclusion criteria, as it includes only adults with obsessive-compulsive disorder (OCD) refractory to serotonin reuptake inhibitor (SRI) monotherapy, whereas the review includes a broader range of patient populations, including schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders."
False," The study population does not match the specified inclusion criteria, as it only includes patients with severe Gilles de la Tourette syndrome, whereas the review focuses on various psychiatric conditions and disorders."
False," The study is a retrospective chart review, which is not a randomized controlled trial or a comparative observational study, and does not meet the inclusion criteria for study design."
False," The article does not report on the effectiveness or harms of medications for patients with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia, as it appears to be a methodological paper discussing the development of an approach for assessing the reliability and validity of single-subject research."
False," The study population does not match the inclusion criteria, as it includes comorbid and comedicated patients with different psychotic disorders, whereas the review only includes patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The study population (nonpsychotic subjects with renal or hepatic impairment) does not match the specified inclusion criteria, which focus on adults and children with various psychiatric disorders."
False," The article does not focus on the effectiveness or harms of antipsychotic medications, but rather on the haematological safety of a specific class of medications."
False," The study does not meet the inclusion criteria for interventions, as it focuses on clozapine, which is not one of the specified interventions (aripiprazole, asenapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone)."
True,"<This study meets all the inclusion criteria, as it is a randomized, double-blind, placebo-controlled trial examining the efficacy and safety of olanzapine in treating acute bipolar mania, which is a relevant population and intervention for this review, and it reports on outcomes of interest such as symptom response, adherence, and persistence.>"
False," The study population does not match the specified inclusion criteria, as it specifically targets adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, whereas the review paper's inclusion criteria are broader, including children and adolescents with various psychiatric disorders."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the comparison of olanzapine and haloperidol, and the assessment of functional outcomes."
False," The study population specified in the abstract (inpatients with schizophrenia) does not match the inclusion criteria, which specify adults, adolescents, and children with various psychiatric conditions."
False," The study population does not match the specified criteria, as it includes only patients with Parkinson's disease (PD) and chronic hallucinations, whereas the review includes various psychiatric and neurodevelopmental disorders."
False, The study population does not match the inclusion criteria as it only includes patients with Parkinson's disease and not the specified psychiatric or neurological conditions.
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial is not explicitly mentioned, but the study is a pilot study and meets the inclusion criteria for being a randomized controlled trial, and the study examines the effectiveness of an intervention (intravenous biperiden) in a population of interest (adults with schizophrenia)."
False," The study population is not adults (age 18 years and older) with schizophrenia or bipolar disorder, but rather older adults (≥ 65 years of age) with behavioral and psychological symptoms of dementia, which is outside the inclusion criteria."
True," The study meets all the inclusion criteria, as it is a randomized controlled trial examining the cost-effectiveness of clozapine compared to conventional antipsychotic medication in patients with schizophrenia in a state hospital, which aligns with the specified population, interventions, and outcomes of interest."
False," The title and abstract indicate that the article reviews pharmacologic agents for the treatment of acute bipolar mania, but does not focus on adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia or other psychotic disorders, which is the specified population of interest."
False," The article's focus is on bipolar disorder therapeutics, particularly maintenance treatment, whereas the inclusion criteria specify a broad range of psychiatric disorders and interventions."
True," The study meets all the inclusion criteria as it focuses on treatment refractory schizophrenia and includes randomized controlled trials, good quality systematic reviews, and comparative observational studies."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effect of clozapine on family burden in patients with refractory schizophrenia, and it reports on the outcome of caregiver burden, which is of interest for this review."
True," The study meets all the inclusion criteria, including the population of interest (patients with treatment-refractory schizophrenia), the intervention (olanzapine), and the study design (randomized controlled trial)."
True," The study meets all the inclusion criteria, including the focus on older adults (≥ 65 years of age) with psychotic disorders, the use of quetiapine as an intervention, and the assessment of effectiveness outcomes such as symptom response and adherence."
True," The study meets all the inclusion criteria, including the population (patients with schizophrenia), interventions (olanzapine, risperidone, and haloperidol), and outcomes (effects on plasma prolactin levels)."
False," The study does not meet the inclusion criteria because it does not involve atypical antipsychotic medications, which are specified in the inclusion criteria."
True," The study meets all the inclusion criteria, including the use of a specific antipsychotic medication (risperidone), the population of interest (first-episode schizophrenia patients), and the study design (randomized controlled trial)."
False," The study does not include any of the specified patient populations (e.g. schizophrenia, bipolar disorder, major depressive disorder) and does not examine any of the specified outcomes (e.g. mortality, quality of life, functional capacity)."
True," The study meets the inclusion criteria as it is a case-control study examining the risk of first-time idiopathic venous thromboembolism in users of conventional antipsychotic drugs, which is a relevant outcome for the review's focus on antipsychotic medications."
False," The study population is bipolar patients, which does not match the inclusion criteria of adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of iloperidone in patients with schizophrenia, which is one of the populations of interest in the review."
True," The study meets the inclusion criteria as it involves adults with schizophrenia who are treatment-resistant, which is a relevant population for the review, and examines the effectiveness of clozapine, which is an included intervention."
False," The study is a case report and literature review, which does not meet the inclusion criteria of being a randomized controlled trial or a good-quality systematic review."
False," The article does not meet the inclusion criteria as it is not a randomized controlled trial, comparative observational study, or systematic review, and it does not report on the effectiveness or harms of atypical antipsychotics in the specified patient populations."
False," The study population only includes adults and adolescents with schizophrenia, and does not include children under the age of 13, which does not meet the inclusion criteria."
False," The article does not match the specified population of interest, which is Tourette syndrome, but rather schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
False," The study population is patients with Parkinson's disease experiencing dopamine-induced psychosis, which does not match the specified inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia or schizoaffective disorder, the intervention of switching from a conventional antipsychotic drug or risperidone to olanzapine, and the study design of a randomized controlled trial."
False," The study does not focus on the effectiveness or harms of antipsychotic medications, but rather aims to establish reference ranges for hematologic parameters in patients with schizophrenia."
False," The study does not meet the inclusion criteria as it is an open study, not a randomized controlled trial, and it does not examine the relationship between improved adherence or persistence and improved outcomes."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of risperidone in patients with schizophrenia, which is a relevant population for the review."
False," The study does not meet the inclusion criteria as it is not a head-to-head randomized controlled trial, but rather a direct comparison between classic and novel antipsychotics."
True," The study meets all inclusion criteria, including a randomized controlled trial design, comparison of risperidone and haloperidol, and evaluation of effectiveness outcomes such as symptom response and quality of life."
False," The study population does not match the inclusion criteria, as it only includes adults and chronically hospitalized inpatients with schizophrenia, whereas the review includes a broader range of patient populations and age groups."
False," The study population does not match the specified inclusion criteria, as the study focuses on adults and adolescents with treatment-resistant depression, whereas the review includes patients with schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
True," The study met all inclusion criteria, including the diagnosis of schizophrenia, the use of risperidone as an intervention, and the examination of effectiveness outcomes such as seclusion and restraint."
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (e.g. aripiprazole, clozapine, etc.) or patient populations (e.g. schizophrenia, bipolar disorder, etc.)."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia, the use of clozapine, and the examination of a pharmacokinetic interaction with ciprofloxacin."
False," The article does not meet the inclusion criteria because it does not specify a particular age group or diagnosis, and its focus is on the treatment of psychosis and agitation in the elderly, which is not one of the specified inclusion criteria."
False," The study population (psychotic patients with criminal histories) does not match the inclusion criteria (patients with schizophrenia, bipolar disorder, major depressive disorder, etc.)."
True," The study meets all inclusion criteria, including the comparison of olanzapine and clozapine in treatment-resistant schizophrenia patients, and the use of a randomized controlled trial design."
False," The study does not meet the inclusion criteria as it is a meta-analysis examining the superiority of atypical antipsychotics to placebo, whereas the review is focused on a broader range of outcomes including effectiveness, harms, and adherence in various patient populations."
False," The study population is not specified in the abstract, but the title mentions ""treatment refractory schizophrenia"", which is included in the inclusion criteria, but the study population is limited to adults (18+ years) with chronic schizophrenia, which is not explicitly stated in the abstract, but it seems to be the case."
True, The study meets the inclusion criteria as it involves children (under 13 years) with bipolar disorder and examines the effects of lithium treatment on brain myo-inositol levels.
True," The article's focus on antipsychotic-induced movement disorders in the elderly population meets the inclusion criteria, and the study's design and population align with the specified inclusion criteria."
True," The article meets all the inclusion criteria, including the focus on the use of risperidone in patients with various disorders other than schizophrenia, the inclusion of randomized controlled trials and observational studies, and the examination of effectiveness and harm outcomes."
False," The article does not focus on the treatment of refractory schizophrenia in adults, as stated in the inclusion criteria."
False," The study only included adults (18 years and older) with schizophrenia, whereas the review includes children (under 13 years) and adolescents (13-17 years) with various diagnoses."
True," The study meets all inclusion criteria, including the diagnosis of schizoaffective disorder, the use of ziprasidone as an intervention, and the assessment of effectiveness outcomes such as symptom response and adverse effects."
True," The study meets all the inclusion criteria, including the population (patients with schizophrenia), interventions (atypical antipsychotics), outcomes (autonomic neurocardiac function), and study design (randomized controlled trial)."
False," The study does not meet the inclusion criteria because it does not involve a randomized controlled trial, systematic review, or comparative observational study examining the effectiveness or harms of quetiapine, but rather a pharmacokinetic study examining the interaction between quetiapine and phenytoin."
False," The study population does not match the specified criteria, as it only includes adults and adolescents with schizophrenia, whereas the review includes a broader range of patient populations, including children, adolescents, and older adults with various diagnoses."
True," This study meets all the inclusion criteria as it involves adults with schizophrenia, uses a relevant intervention (risperidone), and reports on effectiveness outcomes (clinical response, side effects) and harms (parkinsonian side effects) in a randomized controlled trial."
True,"<The study meets the inclusion criteria as it is a randomized controlled trial comparing the efficacy and tolerability of intramuscular ziprasidone with haloperidol in patients with acute psychotic agitation, which is a relevant population for this review, and reports on effectiveness outcomes such as symptom response and adverse events, which are of interest for this review.>"
False," The study population does not match the inclusion criteria, as the study only includes patients with Parkinson's disease and drug-induced psychosis, whereas the review is focused on patients with schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
True," The study meets all inclusion criteria, including a diagnosis of schizophrenia, a randomized controlled trial design, and an examination of the effectiveness of olanzapine."
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia, bipolar disorder, and other specific conditions, but does not include older adults (≥ 65 years of age) with behavioral and psychological symptoms of dementia, which is one of the inclusion criteria."
True," The study compares the clinical and economic outcomes of olanzapine and risperidone in patients with schizophrenia, meeting the inclusion criteria for the review."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia, the use of a randomized controlled trial design, and the examination of the effectiveness of pindolol augmentation in reducing aggression in patients with schizophrenia."
True," The study meets the inclusion criteria as it involves older adults (≥ 65 years of age) with behavioral and psychological symptoms of dementia, and examines the effectiveness and tolerability of atypical antipsychotics (risperidone and olanzapine) in this population."
False," The study population consists of outpatients with treatment-resistant depression, which does not match the specified population of interest (schizophrenia, bipolar disorder, major depressive disorder, etc.)."
True," The study meets all the inclusion criteria as it involves a randomized controlled trial in adults with schizophrenia, examining the long-term effects of olanzapine treatment on weight change and related health factors."
False," The title and abstract do not indicate that the article specifically focuses on adults (age 18 years and older) with schizophrenia, but rather on the pharmacoeconomic evaluation of atypical antipsychotics for schizophrenia in general."
False," The article's focus is on the evaluation of multiple surrogate endpoints in clinical trials, which does not align with the review's focus on the effectiveness and harms of specific medications in various patient populations."
False," The study population is first-episode manic patients with bipolar I disorder, which does not match the inclusion criteria of adults (age 18 years and older) and adolescents (age 13-17 years) with a DSM III-R or DSM-IV diagnosis of bipolar disorder."
False," The article does not match the specified population of interest, which includes adults and adolescents with bipolar disorder, schizophrenia, and other specified conditions, whereas the article focuses on acute mania treatment in adults."
True," The study meets the inclusion criteria as it specifically focuses on the treatment of late-life schizophrenia with neuroleptic medication, which is the topic of interest for the review paper."
False," The study population is not limited to adults with schizophrenia, but also includes Medicaid-eligible recipients with schizophrenia, which may not align with the specified inclusion criteria."
True," The study meets the inclusion criteria as it is a longitudinal study examining the effects of olanzapine and other antipsychotics on cognitive function in patients with chronic schizophrenia, and it reports on effectiveness outcomes such as symptom response and cognitive function."
True," The study meets all inclusion criteria, including a randomized controlled trial design, a specific patient population (women with schizophrenia), and a relevant outcome (symptom response)."
True," The study meets all the inclusion criteria, including the population of interest (patients with treatment-resistant schizophrenia), interventions (second-generation antipsychotics), and outcomes (efficacy and tolerability)."
True," The study meets all inclusion criteria, including the population (first-episode schizophrenia patients), intervention (risperidone treatment), and outcome (basal ganglia volumes)."
False," The study population specified in the abstract (patients with schizophrenia on short-term acute inpatient units) does not match the inclusion criteria, which include a broader range of psychiatric conditions and patient populations."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of quetiapine or haloperidol as interventions, and the assessment of cognitive skills and symptom response."
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, but rather an open, cross-sectional study that only included responders and partial responders to T4 treatment."
False," The study population does not match the specified criteria, as it includes patients with intellectual disability and bipolar spectrum disorders, whereas the review paper is focused on patients with schizophrenia, bipolar disorder, major depressive disorder, and other specific conditions."
False," The study does not meet the inclusion criteria for the population, as it only includes adults and adolescents with psychotic agitation, whereas the review includes various populations with different psychiatric disorders."
True," The study meets the inclusion criteria as it is a randomized controlled trial comparing the effectiveness of risperidone and typical antipsychotics in patients with first-episode schizophrenia, and it reports on outcomes such as hospitalization, symptom levels, and use of medication, which are relevant to the review."
True, The study meets the inclusion criteria as it involves a randomized controlled trial (RCT) examining the effects of olanzapine on the QTc interval in patients with schizophrenia and related psychoses.
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, but rather a randomized switch of patients from Clozaril to generic clozapine and back, with a small sample size and limited follow-up period."
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, but rather a case series with no control group."
False," The study is not a randomized controlled trial, but rather a single case study, and does not meet the inclusion criteria of being a randomized controlled trial, good quality systematic review, or comparative observational study."
True," The study meets all the inclusion criteria, including the population (adults with schizophrenia), interventions (classic and atypical neuroleptics), outcomes (symptom response, side effects, and subjective evaluation of treatment), and study design (comparative observational study)."
False," The study population consists of adults with schizophrenia or schizoaffective disorder, which does not match the inclusion criteria of children, adolescents, and older adults with various psychiatric conditions."
True," The study meets all the inclusion criteria, including the population (outpatients with schizophrenia), interventions (olanzapine, haloperidol, and risperidone), and study design (observational study), and the outcomes (incidence of extrapyramidal symptoms and concomitant use of anticholinergic drugs) are relevant to the review."
False," The article does not meet the inclusion criteria as it focuses on pediatric bipolar disorder, whereas the inclusion criteria specify adults (18 years and older) and adolescents (13-17 years) with schizophrenia, bipolar disorder, and other conditions."
False," The study population does not match the specified criteria, as it includes only two adult males with schizoaffective disorder, whereas the review paper is focused on various psychiatric disorders across different age groups."
False," The title and abstract do not mention schizophrenia, bipolar disorder, major depressive disorder, pervasive developmental disorder, disruptive behavior disorder, or other conditions specified in the inclusion criteria, and the focus is on Alzheimer's disease and related disorders."
False," The study only examines the relationship between the Cys23Ser 5HT2C serotonin receptor polymorphism and schizophrenia, and does not address any of the specified outcomes of interest (e.g. mortality, quality of life, etc.) for any of the patient populations."
False," The study does not examine the effectiveness of the specified medications, but rather the amount of change in instrument scores that represents a clinically detectable improvement or deterioration in patients with schizophrenia."
False," The study does not meet the inclusion criteria for interventions, as it only examines the effects of olanzapine and risperidone, which are not included in the list of interventions specified in the inclusion criteria."
False," The study does not meet the inclusion criteria as it is a data mining study examining the association between antipsychotic drugs and heart muscle disorder, whereas the review paper is focused on the effectiveness and harms of antipsychotic drugs in various patient populations."
False," The study population is treatment refractory schizophrenia patients, which does not match the inclusion criteria for schizophrenia patients, which includes first episode schizophrenia or patients refractory to treatment."
True," The study meets all inclusion criteria, including the population (schizophrenic patients), interventions (atypical antipsychotic drugs), and outcomes (subjective well-being, symptom response) of interest."
True, The study meets all the inclusion criteria as it is a randomized controlled trial examining the effectiveness of risperidone versus haloperidol in long-term hospitalized chronic patients with schizophrenia.
False," The study population is children with a schizophrenic parent, whereas the review criteria specify a focus on adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of antipsychotic drugs (olanzapine, haloperidol, and risperidone), and the examination of weight change as an outcome."
False,"<The study population does not match the inclusion criteria, as the study focuses on adolescents with subaverage cognitive abilities and disruptive behavior disorders, whereas the review is focused on adults and adolescents with various psychiatric conditions, including schizophrenia, bipolar disorder, and pervasive developmental disorders.>"
False," The study population does not match the inclusion criteria as the study focuses on adults and adolescents with bipolar I disorder, whereas the review includes children, adolescents, and adults with various psychiatric disorders."
False," The study population is not limited to adults (age 18 years and older) with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia, but also includes children and adolescents with pervasive developmental disorders and disruptive behavior disorders."
False," The article is about a method for determining clozapine and desmethylclozapine levels in human plasma, but it does not meet the inclusion criteria as it does not relate to the treatment of any of the specified conditions or the assessment of any of the specified outcomes."
True," The study meets all the inclusion criteria, including the population of interest (patients with schizophrenia treated with olanzapine), the interventions (olanzapine), and the outcomes (hyperglycemia)."
True,"<This study meets all the inclusion criteria, including the diagnosis of psychosis and the use of ziprasidone as an intervention, and the study design is a randomized controlled trial, which is included in the review criteria.>"
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of olanzapine and haloperidol as interventions, and the measurement of prolactin levels as an outcome."
False," The paper does not focus on the effectiveness and harms of amisulpride in schizophrenia, but rather on the practical use of amisulpride in treatment, which does not match the inclusion criteria."
True," The study focuses on the treatment of suicidality in schizophrenia, which is within the scope of the review paper."
True," The study meets all the inclusion criteria, including a randomized controlled trial design, comparison of risperidone and haloperidol, and examination of the speed of onset of therapeutic effect in patients with schizophrenia."
False," The study population does not match the specified population of interest, as it only includes patients switching to ziprasidone from other antipsychotics, whereas the review focuses on patients with various psychiatric disorders."
False, The article does not meet the inclusion criteria as it is a methodological paper on statistical analysis and does not report on the effectiveness or harms of a specific intervention in a specific population.
True," The study meets the inclusion criteria as it involves children (under 13 years) with a DSM-III-R or DSM-IV diagnosis of a pervasive developmental disorder, including autistic disorder."
False, The study does not involve any of the specified patient populations or interventions.
False," The abstract does not mention any specific interventions or outcomes related to the inclusion criteria, and the focus is on neurodegenerative diseases rather than psychiatric disorders."
False," The study is a meta-analysis of the use of typical antipsychotic agents in bipolar disorder, but it does not meet the inclusion criteria as it does not focus on the effectiveness or harms of atypical antipsychotics, which are the interventions of interest for this review."
False," The population of interest specified in the abstract (e.g., patients with schizophrenia, bipolar disorder, major depressive disorder, etc.) does not match the inclusion criteria, which only specify adults (age 18 years and older) with schizophrenia."
True," The study meets the inclusion criteria as it is a randomized controlled trial (double-blind, placebo-controlled) comparing the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol for the treatment of acute agitation in schizophrenia, which is a relevant population and outcome for the review."
False, The study does not focus on a specific population or disorder mentioned in the inclusion criteria.
False," The article's focus on long-term care for patients with dementia and their caregivers does not match the specified inclusion criteria, which pertain to various psychiatric and developmental disorders."
True," The study meets all the inclusion criteria, including the population (adults and adolescents with schizophrenia), interventions (antipsychotic drugs), and outcomes (dropout rates, adherence, and persistence)."
True," The study meets all the inclusion criteria as it focuses on the effects of long-term antipsychotic treatment on serum leptin levels in patients with schizophrenia, which is a relevant population for this review, and the study design is a cohort study, which is included in the criteria."
True," The study meets all inclusion criteria, including the comparison of antipsychotic drugs for the treatment of schizophrenia, and the use of meta-analysis to evaluate the efficacy of newer antipsychotic drugs."
True," The study meets all the inclusion criteria as it involves substance abusers with psychosis, is a randomized controlled trial, and examines the safety and efficacy of risperidone."
False," The study is not examining the effectiveness of sertindole in patients with schizophrenia or other psychiatric conditions, but rather comparing mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other antipsychotic drugs."
True," The study meets all the inclusion criteria, including the population (patients with schizophrenia), interventions (risperidone and olanzapine), and outcomes (efficacy and tolerability) of interest."
False," The study population is adults with post-traumatic stress disorder (PTSD), which does not match the inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions."
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of perospirone in patients with schizophrenia, which is a population of interest in the review."
True," The study meets all the inclusion criteria, including a focus on mood stabilizers, a relevant population (individuals with bipolar disorder), and relevant outcomes (efficacy and harms of mood stabilizers)."
False," The study population does not match the specified inclusion criteria, as it only includes schizophrenic patients, whereas the review includes a broader range of patient populations."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder, which falls within the scope of the review's inclusion criteria."
True,"<The study meets the inclusion criteria of being a randomized controlled trial examining the efficacy and safety of a medication (olanzapine) for treating agitation in patients with bipolar mania, which is a relevant population for this review.>"
True," The study focuses on drug interactions involving risperidone, which is a medication used in the treatment of various psychiatric disorders, meeting the inclusion criteria."
True," The study meets all the inclusion criteria, including the population (patients with schizophrenia refractory to typical and atypical antipsychotics), intervention (olanzapine), and outcomes (efficacy and harms)."
False," The article does not meet the inclusion criteria as it does not focus on the treatment of psychosis in adults or adolescents with schizophrenia or other psychotic disorders, but rather discusses the ethical issues of intervening prior to making a diagnosis of psychosis."
True," The study meets all the inclusion criteria, including the diagnosis of severe chronic schizophrenia, the use of clozapine and risperidone as interventions, and the inclusion of effectiveness and harms outcomes."
False," The study population only includes adults and adolescents with psychotic mood disorders, whereas the review includes children and adolescents with pervasive developmental disorders and disruptive behavior disorders."
True," The study meets all the inclusion criteria, including a diagnosis of schizophrenia, a focus on adherence, and a study design that examines the relationship between adherence and outcomes."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia, the use of quetiapine, and the assessment of 5-HT2A receptor blockade."
True," The study meets all the inclusion criteria, including the population (schizophrenia patients), interventions (guanfacine adjunctive treatment to neuroleptics), and study design (randomized controlled trial)."
False," The study focuses on children and adolescents with mental disorders, whereas the review paper is focused on adults and older adults with schizophrenia, bipolar disorder, and other conditions."
False," The study focuses on the cost-effectiveness of atypical antipsychotics for various psychiatric disorders, but the abstract does not specify the inclusion of adults (18 years and older) with schizophrenia."
True,"The study meets all the inclusion criteria, as it involves a randomized controlled trial of olanzapine versus haloperidol in patients with schizophrenia, and reports on effectiveness and harm outcomes."
False," The study population and interventions do not match the specified inclusion criteria, as the study focuses on personality and social functioning in relation to neurotransmitters, temperament, and character dimensions, but does not address the specific psychiatric conditions and medications listed in the inclusion criteria."
False," The study population does not match the specified inclusion criteria, as it only includes adult males with schizophrenia, whereas the review paper includes a broader range of populations with various psychiatric conditions."
True," The article meets all the inclusion criteria, including the population of interest (schizophrenia), the intervention (risperidone), and the study design (meta-analysis of controlled trials)."
False," The study does not meet the inclusion criteria as it focuses on the use of placebo in antipsychotic clinical trials, rather than evaluating the effectiveness of specific antipsychotic medications."
False," The article does not meet the inclusion criteria as it is not a randomized controlled trial, but rather a comparative observational study."
True," The study meets all the inclusion criteria, including the population (adults with schizophrenia), interventions (risperidone), and outcomes (efficacy as measured by symptom response)."
False," The study population only includes patients with bipolar I disorder in hospital settings, which does not match the inclusion criteria of adults with bipolar disorder, including manic or depressive phases."
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia or schizoaffective disorder, whereas the review paper includes a broader range of patient populations."
False," The article does not meet the inclusion criteria because it is a case report and not a randomized controlled trial, comparative observational study, or systematic review, which are the types of studies included in this review."
True," The study meets all inclusion criteria, including the population (patients with schizophrenia), interventions (clozapine and haloperidol), outcomes (efficacy, adverse effects), and study design (randomized controlled trial)."
False," The study does not meet the inclusion criteria as it does not involve a randomized controlled trial, which is a required study design for inclusion in the review."
True," The study investigates the pathophysiology of weight gain during treatment with olanzapine for schizophrenia, which aligns with the inclusion criteria of focusing on interventions for schizophrenia."
False," The paper's focus is on the clinical pharmacology, efficacy, and safety of ziprasidone, not on the comparison of ziprasidone with other medications, which is the focus of the review paper."
False," The study population does not match the inclusion criteria, as the study is focused on patients with juvenile neuronal ceroid lipofuscinoses, which is not one of the specified conditions."
True," The study meets the inclusion criteria as it involves patients with schizophrenia or schizoaffective disorder, uses electronic monitoring devices to estimate medication compliance, and examines the relationship between adherence and outcomes."
True," The study meets the inclusion criteria for the review, as it is a randomized controlled trial examining the effectiveness of olanzapine as adjunctive therapy in patients with treatment-resistant bipolar disorder, which is a relevant population for this review."
True," The study meets the inclusion criteria as it involves a randomized controlled trial of clozapine, a medication included in the review, in patients with schizophrenia, a population included in the review, and examines effectiveness outcomes such as symptom response and neurocognition, which are relevant to the review."
False," The study population does not match the specified criteria as it only includes adults and adolescents with schizophrenia, whereas the review includes a broader range of populations such as bipolar disorder, major depressive disorder, and dementia."
True," The study population includes adults with schizophrenia, including other psychotic disorders, and bipolar disorder, which matches the inclusion criteria."
True," The study meets the inclusion criteria as it involves in vivo 123I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients, which is a relevant topic for the review, and it is a randomized controlled trial."
False," The study focuses on the autonomic responses of patients with schizophrenia treated with olanzapine or clozapine, but it does not meet the inclusion criteria as it is not a randomized controlled trial, systematic review, or observational study examining the effectiveness or harms of the specified antipsychotic medications."
True," The article meets all the inclusion criteria, as it is a systematic review examining the efficacy of fluvoxamine as an adjunctive agent in schizophrenia, a condition that is included in the scope of the review."
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, comparative observational study, or systematic review, and it does not examine the relationship between adherence or persistence and improved outcomes."
True," The study meets all the inclusion criteria, including the population (medication-refractory schizophrenia), intervention (olanzapine), and outcomes (cognitive function)."
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of antipsychotic medications in reducing hostility in patients with schizophrenia.
False," The article does not meet the inclusion criteria because it does not focus on the effectiveness or harms of antipsychotic medications in the specified patient populations, but rather reviews the risk of torsade de pointes and sudden death associated with these medications."
False," The study population consists of patients with recent-onset schizophrenia who have been clinically stabilized on maintenance antipsychotic treatment for at least 1 year, which does not match the inclusion criteria of patients with schizophrenia (including first episode and treatment resistance)."
False,"<the article does not meet the inclusion criteria as it is a case series and not a randomized controlled trial, a comparative observational study, or a good quality systematic review>."
False,"<The study population of the article does not match the specified inclusion criteria, as it focuses on patients with bipolar I disorder, whereas the review includes patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, among other conditions.>"
False," The study population of individuals with developmental disabilities does not match the specified inclusion criteria, which focus on various psychiatric and neurodevelopmental disorders."
True," The study meets the inclusion criteria as it is a randomized double-blind study comparing the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients, which is relevant to the review's focus on effectiveness and harms of antipsychotic medications in various patient populations."
True," The study meets the inclusion criteria as it focuses on adults with schizophrenia, uses a randomized controlled design, and examines the effectiveness of a specific medication (ipsapirone) in a relevant outcome (endocrine response)."
False," The study does not report on the effectiveness or harms of quetiapine, but rather a case series of adverse effects."
True," The study meets all the inclusion criteria as it involves adults with schizophrenia, includes a discussion of clozapine-induced diabetes mellitus and diabetic ketoacidosis, and presents original research using the euglycemic clamp study to demonstrate insulin resistance."
False," The study population does not match the inclusion criteria, as it only includes high-schizotypal normals and schizophrenic patients, whereas the inclusion criteria specify a broader range of psychiatric disorders and patient populations."
True," The study meets all the inclusion criteria, including the population (schizophrenic outpatients), interventions (maintenance medication and intermittent medication strategies), outcomes (relapse prevention, psychopathology, social adjustment, subjective well-being, and side-effects), and study design (randomized controlled trial)."
True," The article meets all the inclusion criteria, including being a randomized controlled trial or a good quality systematic review, examining the effectiveness of amisulpride in patients with schizophrenia, and reporting on outcomes such as symptom response, quality of life, and adverse effects."
True," The study meets the inclusion criteria as it examines the relationship between antipsychotic use and sudden cardiac death, a life-threatening adverse event, in a cohort study design."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia and the use of clozapine, and reports on the risk of diabetes, hyperlipidemia, and hypertension, which are relevant outcomes for this review."
True," The study meets the inclusion criteria as it examines the relationship between affective reactivity of language and right-ear advantage in schizophrenia, which is a relevant topic for the review."
False," The study population is not specified in the abstract, but the inclusion criteria mention specific age ranges and diagnoses that are not mentioned in the abstract, suggesting that the study may not meet the inclusion criteria."
True," The study meets all the inclusion criteria, including the population (adults with schizophrenia), intervention (quetiapine vs haloperidol), and outcome measures (cognitive function)."
False," The study does not meet the inclusion criteria as it is not focused on the specified patient populations (adults with schizophrenia, bipolar disorder, major depressive disorder, and older adults with behavioral and psychological symptoms of dementia) or interventions (atypical antipsychotics) mentioned in the inclusion criteria."
True," The study meets all inclusion criteria, including the population of interest (patients with treatment-resistant schizophrenia), the intervention (clozapine), and the study design (cost-utility analysis)."
False," The article does not meet the inclusion criteria as it is a descriptive epidemiologic study of spontaneous adverse event reports of hyperglycemia occurring in clozapine-treated patients, rather than a randomized controlled trial, systematic review, or comparative observational study examining the effectiveness or harms of clozapine in the specified patient populations."
False," The article does not meet the inclusion criteria as it is a head-to-head comparison of two antipsychotics (haloperidol and risperidone) in patients with dementia, whereas the review focuses on randomized controlled trials, good quality systematic reviews, and comparative observational studies in patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The article does not meet the inclusion criteria as it is about rapid cycling in bipolar disorder, which is not the focus of the review, and it does not mention any of the specified interventions or outcomes."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effects of ethyl-eicosapentaenoate on patients with persistent schizophrenia symptoms, which is within the scope of the review."
True," The study meets the inclusion criteria as it involves a randomized, placebo-controlled design, includes a DSM-IV diagnosis of schizophrenia, and examines the effectiveness of olanzapine, which is an included medication."
False," The study population does not match the inclusion criteria as it only includes patients with clozapine-induced hypersalivation, which is not one of the specified patient populations."
True," The study meets all inclusion criteria, including the population (outpatients with schizophrenia and other psychotic disorders), interventions (quetiapine and risperidone), and outcomes (safety, efficacy, and tolerability) of interest."
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, bipolar disorder, and major depressive disorder, and examines the pharmacovigilance of olanzapine, which is an included intervention."
False," The study does not meet the inclusion criteria as it is a letter to the editor and does not report a randomized controlled trial, but rather a critique of another study."
False," The study population in the abstract is limited to patients with a diagnosis of schizoaffective disorder, whereas the inclusion criteria specify a broader range of diagnoses, including schizophrenia, bipolar disorder, major depressive disorder, and others."
False," The study population is not specified in the inclusion criteria, which only mention adults and children with various psychiatric conditions, whereas the study focuses on female patients with borderline personality disorder."
True," The study investigates the psychometric properties of the Behavioural Activity Rating Scale (BARS) in acutely agitated patients with psychosis, which aligns with the inclusion criteria of the review."
True," The study meets the inclusion criteria as it involves a randomized controlled trial of olanzapine in patients with schizophrenia and comorbid substance abuse disorders, which is a relevant population for this review."
True," The study meets all the inclusion criteria, including a randomized controlled trial design, a comparison of two antipsychotic medications (risperidone and haloperidol), and an evaluation of the risk of relapse in patients with schizophrenia."
False," The study population specified in the abstract does not match the inclusion criteria, which are focused on adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and other conditions, whereas the study is focused on patients with bipolar disorder who are partially nonresponsive to valproate or lithium monotherapy."
False," The study does not meet the inclusion criteria as it is a pilot study and a letter to the editor, and not a randomized controlled trial."
False," The study is a case study using an experimental ABAB design, which does not meet the inclusion criteria of being a randomized controlled trial, good quality systematic review, or comparative observational study."
False," The study population does not match the inclusion criteria, as it includes only patients with unipolar psychotic depression, whereas the review focuses on patients with schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
False," The study population does not match the inclusion criteria as it only includes adults and older adults, whereas the review includes children, adolescents, and adults with various psychiatric disorders."
True," The study meets all the inclusion criteria as it investigates the effects of risperidone on the hypothalamo—pituitary—gonadal (HPG) axis in schizophrenia, a condition included in the review, and reports on effectiveness outcomes such as symptom response and adherence."
False," The study population does not match the inclusion criteria, as it specifically includes adults (age 18 years and older) with schizophrenia, bipolar disorder, and major depressive disorder, but excludes older adults with behavioral and psychological symptoms of dementia, which is the focus of this study."
True," The study meets all the inclusion criteria as it is a randomized controlled trial (RCT) examining the effectiveness of risperidone in treating Tourette syndrome, which is within the scope of the review, and it reports on relevant outcomes such as efficacy, tolerability, and adverse effects."
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, and it does not focus on the specified patient populations or interventions."
True," The study meets all the inclusion criteria, as it is a randomized controlled trial examining the effectiveness and safety of amisulpride in the treatment of acute schizophrenia."
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of amisulpride in adult patients with schizophrenia, examining its effects on social functioning and quality of life."
False," The study population is not specified as adults with schizophrenia, but rather as a group of 12 schizophrenic patients receiving high-dose glycine in addition to antipsychotic treatment, which does not match the inclusion criteria."
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial design, and examines the effectiveness of melperone in improving psychiatric status and reducing extrapyramidal symptoms."
False," The study population does not match the inclusion criteria, as it includes patients with Parkinson's disease and dementia, which is not specified in the inclusion criteria."
True," The article meets all the inclusion criteria, as it is a randomized controlled trial examining the effectiveness of olanzapine in patients with schizophrenia, a relevant population for the review."
False," The study population of this paper includes patients with bipolar and schizoaffective disorders, which does not match the inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False, The study does not meet the inclusion criteria as it is not a randomized controlled trial or a comparative observational study examining the effectiveness of olanzapine versus other antipsychotics in the treatment of schizophrenia.
True,"The article meets all the inclusion criteria, including the population of interest (adults with schizophrenia), interventions (atypical antipsychotic medications), and outcomes (efficacy, adherence, and persistence)."
True," The study meets all the inclusion criteria, including the population of interest (patients with schizophrenia), the intervention (amisulpride), and the study design (randomized controlled trials)."
True," The study meets all the inclusion criteria, including the focus on adults and adolescents with schizophrenia and schizoaffective disorder, the use of atypical antipsychotics, and the inclusion of randomized controlled trials."
True," The study meets all the inclusion criteria, as it includes a case report of a patient with first-episode schizophrenia who was treated with clozapine and experienced a sustained resolution of symptoms, and it is a randomized controlled trial examining the effectiveness of clozapine in treating schizophrenia."
False," The study population does not match the inclusion criteria as it only includes first admission psychotic persons with psychosis, whereas the review includes a broader range of diagnoses."
False," The article's inclusion criteria do not match the title and abstract, which suggest a focus on olanzapine in acute bipolar mania, whereas the inclusion criteria mention a broader range of diagnoses and outcomes."
False," The article does not meet the inclusion criteria as it focuses on the effects of antipsychotic medication on glucose and lipid regulation, but does not specifically address the inclusion criteria of examining the relationship between improved adherence or persistence and improved outcomes, nor does it specifically focus on the populations of interest (schizophrenia, bipolar disorder, etc.)."
True," The study meets all inclusion criteria, including a population of patients with schizophrenia, the use of clozapine as an intervention, and the examination of the effect of influenza vaccination on serum clozapine concentrations."
False," The study population is patients with Parkinson's disease and drug-induced psychosis, which does not match the inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, or other specified conditions."
False," The article does not meet the inclusion criteria as it is about the epidemiology of primary blepharospasm, a dystonia disorder, and does not focus on the treatment or management of psychiatric disorders."
False," The study population includes patients with schizoaffective disorder, but the inclusion criteria specify that the review only includes patients with schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of risperidone as an intervention, and the measurement of cytokine profiles as an outcome."
True," The study meets all inclusion criteria, including a focus on adults with schizoaffective disorder, bipolar type, and a randomized controlled trial design comparing olanzapine to haloperidol."
True," The study meets all inclusion criteria, including a randomized controlled trial design, a focus on schizophrenia, and the inclusion of effectiveness outcomes such as symptom response and quality of life."
False," The study population includes patients with schizophrenia and related disorders, which is not within the specified inclusion criteria of adults and adolescents with a diagnosis of schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
False," The article does not meet the inclusion criteria as it is not about the effectiveness of atypical antipsychotics in the specified patient populations, but rather discusses their potential use as augmenting agents in treatment-resistant depression."
True," The study meets the inclusion criteria as it is a retrospective study evaluating the economic outcomes of olanzapine versus risperidone in the treatment of schizophrenia, and it reports on effectiveness outcomes relevant to the review, including treatment duration and direct costs."
False," The study population is not limited to the specified age groups (e.g., older adults, children under 13 years), and the interventions and outcomes of interest are not fully aligned with the review's inclusion criteria."
True," The study meets all the inclusion criteria, including the population of interest (schizophrenic patients treated with clozapine), the intervention (acute tryptophan depletion), and the study design (randomized controlled trial)."
False," The article does not meet the inclusion criteria as it does not include the specified interventions (e.g. aripiprazole, asenapine) or outcomes (e.g. mortality, quality of life) for the patient populations of interest (e.g. schizophrenia, bipolar disorder, major depressive disorder)."
False," The study population, intervention, and outcomes do not match the specified criteria for the review, as the study focuses on the treatment of female sexual dysfunction associated with SSRIs, whereas the review focuses on the treatment of various psychiatric disorders."
False," The study does not meet the inclusion criteria as it involves typical antipsychotics (haloperidol and perphenazine) which are not among the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone)."
True," The study meets all inclusion criteria, including the focus on schizophrenia and related disorders, the use of atypical or conventional antipsychotics, and the examination of time to discontinuation, relapse, and compliance."
False," The study population of the paper (schizophrenic patients) does not match the inclusion criteria (schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia)."
False," The study does not meet the inclusion criteria as it is focused on bipolar disorder and the relationship between medication status and cerebellar blood volume, whereas the review is focused on schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the pharmacokinetics and safety of quetiapine when coadministered with other antipsychotics, which is a relevant intervention for the review."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness and tolerability of combination therapy with quetiapine and fluoxetine or imipramine in patients with schizophrenia, schizoaffective disorder, or bipolar disorder."
True," The study meets the inclusion criteria as it involves a randomized, parallel-group, double-blind design comparing the anxiolytic efficacy of ziprasidone with diazepam and placebo in subjects anxious before dental surgery."
True," The article meets all the inclusion criteria, as it is a study on the efficacy and safety of topiramate in the treatment of bipolar disorder, which is a relevant population for the review, and it reports on outcomes that are included in the review, such as efficacy, adherence, and persistence."
False," The study population does not match the inclusion criteria, as it focuses on Alzheimer's disease patients with delusions of theft, whereas the review includes patients with various psychiatric and neurological conditions."
True," The study meets the inclusion criteria as it involves a large national sample of patients with schizophrenia, compares the prevalence of diabetes mellitus in patients receiving prescriptions for atypical and typical neuroleptics, and uses administrative data from the Veterans Health Administration."
True," The study meets all inclusion criteria, including examining racial disparities in antipsychotic prescription patterns for patients with schizophrenia, using a large sample size, and including relevant outcomes such as symptom response and adherence."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia, the use of antipsychotic medications, and the assessment of glucose regulation."
False," The study population is acutely agitated patients with dementia, which does not match the inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
False," The study population does not match the inclusion criteria, as it specifically focuses on treatment-resistant schizophrenia, whereas the review includes a broader range of psychiatric disorders."
False," The study population and interventions mentioned in the title and abstract do not match the inclusion criteria, as the study focuses on the augmentation of SSRIs with atypical antipsychotics in the treatment of depression, whereas the inclusion criteria specify a range of psychiatric disorders and interventions."
False," The study population specified in the inclusion criteria (children and adolescents with pervasive developmental disorders) is not the focus of the current study, which is on the use of atypical antipsychotics in autism."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of risperidone as an atypical antipsychotic, and the assessment of prepulse inhibition of the startle response."
True," The article meets all the inclusion criteria, including the focus on older adults (≥ 65 years of age) with behavioral and psychological symptoms of dementia, and the use of olanzapine as an intervention."
False," The study does not focus on the specified psychiatric disorders or interventions, and the population of interest (patients with paraphilic disorders) does not match the inclusion criteria."
False," The article does not report on the outcome of mirtazapine overdose, but rather mentions it in the title as a case report with a benign outcome, which is not relevant to the review's focus on the effectiveness and harms of mirtazapine in various patient populations."
False," The article is about the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of ziprasidone, but it does not meet the inclusion criteria of focusing on adults (age 18 years and older) with a DSM III-R or DSM-IV diagnosis of schizophrenia, including other psychotic disorders."
True," The study meets all the inclusion criteria as it involves adults with schizophrenia, is a randomized controlled trial, and examines the effectiveness of intramuscular olanzapine in treating acute agitation."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the type of intervention (skills training with manual-based community support sessions), and the outcome measures (social adjustment and quality of life)."
False," The study population does not match the specified criteria, as the study only includes patients with dementia and behavioral disturbances, whereas the review focuses on various psychiatric disorders."
False," The study population of patients with schizophrenia who have gained weight during clozapine treatment does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The study population is adults with psychiatric disorders, not specifically individuals with schizophrenia or other disorders mentioned in the inclusion criteria."
True," The study meets the inclusion criteria as it investigates the association between antipsychotic-induced weight gain and therapeutic response in patients with schizophrenia and schizoaffective disorder, and it is a randomized controlled trial."
True," The study meets all the inclusion criteria, including a focus on adults with schizophrenia, a randomized controlled trial design, and an examination of effectiveness outcomes such as symptom response."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of olanzapine as an intervention, and the examination of effectiveness outcomes such as symptom response and adverse effects."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of clozapine as an intervention, and the examination of effectiveness outcomes such as symptom response and adherence."
True," The study compares the metabolic side effects of risperidone and olanzapine in inpatients, which is relevant to the review's focus on atypical antipsychotics and their effects on various patient populations."
True," The study meets the inclusion criteria as it investigates the effects of neuroleptic medications on thought disorder in patients with schizophrenia, using a randomized controlled design and measuring clinically rated thought disorder, semantic processing, and other relevant outcomes."
False," The article does not focus on schizophrenia, but rather on physical consequences of schizophrenia and its treatment, which is a broader topic than the specified inclusion criteria."
True," The study meets all inclusion criteria, including the comparison of two specific interventions (olanzapine and divalproex) in a randomized controlled trial for the treatment of acute mania in adults and adolescents, which is a relevant population for this review."
True," The study meets all inclusion criteria, including the focus on adults and adolescents with schizophrenia or schizoaffective disorder, the use of randomized controlled trials, and the examination of the effectiveness of specific antipsychotic medications."
True," The study meets the inclusion criteria as it is a randomized controlled trial (RCT) examining the effectiveness of a medication (celecoxib) in combination with an antipsychotic (risperidone) in patients with schizophrenia, which is the focus of the review."
False," The study does not investigate the effectiveness or harms of olanzapine, but rather the effect of fluoxetine addition on olanzapine-induced weight gain."
True," The study meets the inclusion criteria for population (adults and adolescents with schizophrenia and other psychotic disorders), interventions (atypical antipsychotics), and outcomes (effectiveness and harms) as specified in the review paper."
True," The study meets all the inclusion criteria, including the population (treatment-refractory schizophrenia patients), interventions (olanzapine and risperidone), and study design (randomized controlled trial)."
False," The study population does not match the inclusion criteria, as it appears to be focused on schizophrenia, but the inclusion criteria specify a broad range of psychiatric conditions, including bipolar disorder, major depressive disorder, and dementia."
False," The study population is adults and adolescents with various psychiatric disorders, but the article specifically focuses on the risk of new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics, which is not the primary focus of the review."
False," The study only focuses on risperidone, whereas the review is interested in a broader range of antipsychotic medications."
False, The study does not meet the inclusion criteria because it focuses on a specific population (New Hampshire beneficiaries with schizophrenia or schizoaffective disorder) and does not examine the effectiveness of specific antipsychotic medications.
True," The study meets all the inclusion criteria, including the population (patients with schizophrenia), interventions (haloperidol and risperidone), and outcomes (neurocognitive effects) of interest, and it is a randomized controlled trial, which is the preferred study design for inclusion."
False,"<The study population does not match the specified inclusion criteria, as the study focuses on an indigent patient population from a county-operated mental health care system, whereas the review is focused on a broader range of patient populations, including adults, adolescents, and children with various psychiatric disorders.>"
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of bupropion for smoking cessation in patients with schizophrenia, which is a relevant population for this review."
True, The study meets the inclusion criteria as it is a systematic review of randomized controlled trials comparing clozapine with newer atypical antipsychotic drugs for schizophrenia.
True," The study meets all the inclusion criteria, including the specific population (patients with primary negative symptoms of schizophrenia), intervention (D-cycloserine added to risperidone), and outcomes (effectiveness and harms) of interest."
True,"<The study meets all the inclusion criteria: it is a randomized controlled trial, the population of interest (outpatients with stable schizophrenia) is included, the intervention (ziprasidone) is included, and the outcomes (efficacy, harms) are relevant to the review.>"
False," The study population does not match the inclusion criteria, as it only includes outpatients prescribed clozapine, whereas the review paper includes a broader range of patient populations and disorders."
False,"<The study population does not match the inclusion criteria as it only includes adults and adolescents with bipolar disorder, whereas the review includes a broader range of populations, including schizophrenia, major depressive disorder, and pervasive developmental disorders.>"
False," The article does not meet the inclusion criteria as it does not focus on a specific psychiatric disorder, but rather discusses the relationship between Klinefelter's syndrome and psychiatric disorders in general."
True," The study meets the inclusion criteria as it examines the effects of risperidone on the peripheral noradrenergic system in patients with schizophrenia, a population of interest for this review, and uses a randomized controlled design."
True," The study meets all inclusion criteria, including the population of interest (patients with schizophrenia), the intervention (clozapine), and the study design (retrospective cohort study)."
False," The study population in the paper is adults with bipolar I disorder, which does not match the inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
False," The study population does not match the specified inclusion criteria, as it only includes patients with schizophrenia, whereas the review includes a broader range of psychiatric conditions."
True, The study meets the inclusion criteria as it is a randomized controlled trial (head-to-head comparison of two antipsychotics) that investigates the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia.
True," The article meets all the inclusion criteria, including the population of interest (schizophrenic patients), interventions (clozapine), and outcomes (aggression reduction)."
False," The study does not meet the inclusion criteria because it is a retrospective epidemiologic survey of spontaneously reported adverse events, whereas the review includes randomized controlled trials, good quality systematic reviews, and comparative observational studies."
True," The article meets all the inclusion criteria, including the focus on schizophrenia, the inclusion of randomized controlled trials and systematic reviews, and the consideration of effectiveness outcomes such as mortality, quality of life, and functional capacity."
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing amisulpride with haloperidol and risperidone in the treatment of acute exacerbations of schizophrenia, and reports on effectiveness outcomes such as symptom response and adverse effects."
True," The study meets the inclusion criteria as it is a systematic review of experimental and observational studies evaluating clozapine-treated subjects in treatment-resistant schizophrenia, which is a relevant population for the review."
False," The article does not meet the inclusion criteria as it is a review paper that includes multiple interventions (antipsychotics) and patient populations, whereas the review paper is likely focused on a specific intervention (olanzapine and risperidone) and patient population."
True," The study meets all the inclusion criteria, including the population of interest (moderately ill Asian patients with schizophrenia), the intervention (switching to olanzapine), and the study design (randomized controlled trial)."
True," The study meets all inclusion criteria, including the focus on a specific antipsychotic medication (risperidone), the population (inpatients in New York State psychiatric hospitals), and the outcomes (1-year discharge rates)."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of risperidone in children with autistic disorder and serious behavioral problems, which is a relevant population for this review."
False," The study population does not match the specified inclusion criteria, as it only includes patients with schizophrenia and not the other specified diagnoses."
True," The article meets all the inclusion criteria, including a focus on adults and adolescents with schizophrenia, schizoaffective disorder, and bipolar disorder, and the evaluation of ziprasidone as an intervention."
False," The study population is children with subaverage intelligence, which does not match the inclusion criteria of adults and adolescents with various psychiatric conditions."
True, The study meets the inclusion criteria as it is a population-based nested case-control study examining the association between olanzapine and diabetes in patients with schizophrenia.
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of ziprasidone as an intervention, and the evaluation of effectiveness outcomes such as relapse and symptom response."
True," The study meets all the inclusion criteria as it is a randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in patients with bipolar disorder, and it includes outcomes such as clinical remission, health-related quality of life, and work status."
True," The study meets all the inclusion criteria as it is a randomized controlled trial, it investigates the relationship between CYP1A2 activity and clozapine clearance, and it uses a nonlinear mixed-effect modelling method to analyze the data."
True," The article meets all inclusion criteria, including the population of interest (adults with various psychiatric disorders), interventions (atypical antipsychotics), and outcomes (effectiveness and harms), and the study design (systematic review of randomized controlled trials and observational studies)."
False," The study population does not match the inclusion criteria as it only includes adults with bipolar disorder, whereas the review is focused on patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, among other conditions."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia or schizo-affective disorder, the use of novel antipsychotic drugs, and the examination of long-term consequences of switching from conventional to novel antipsychotic drugs."
False," The study was a case series and not a randomized controlled trial, which is a type of study that is excluded from the review."
True," The study meets all the inclusion criteria, as it is a randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in Japanese patients with schizophrenia, and it reports on the primary outcome of interest (extrapyramidal symptoms)."
False," The study does not meet the inclusion criteria as it does not focus on the specified interventions or outcomes for the specified populations, and instead provides a general review of second-generation antipsychotics."
False," The study population does not match the specified criteria, as the study focuses on the Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders, whereas the specified inclusion criteria are for studies on schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
False," The study population does not match the specified criteria, as it only includes patients with first episode psychosis, whereas the review includes patients with various psychotic disorders, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The study population specified in the abstract (schizophrenia, bipolar disorder, major depressive disorder, dementia, pervasive developmental disorders, and disruptive behavior disorders) does not match the specified inclusion criteria (Adults with schizophrenia, including other psychotic disorders, and adults with bipolar disorder, major depressive disorder, and older adults with dementia)."
False," The study population does not match the specified inclusion criteria, as it only includes patients with Parkinson's disease, whereas the review focuses on various psychiatric conditions."
False," The study population consists of residents with dementia, which does not match the inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
True," The study meets all the inclusion criteria as it is a review of pharmacogenomics in schizophrenia, includes adults and adolescents with a DSM III-R or DSM-IV diagnosis of schizophrenia, and examines the effectiveness and harms of various antipsychotic medications."
False," The study does not meet the inclusion criteria because it only includes patients with chronic schizophrenia, whereas the review includes patients with a broader range of diagnoses, including first episode schizophrenia and other psychotic disorders."
False," The study population specified in the abstract does not match the inclusion criteria, which focuses on adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and other conditions, but not autistic disorder."
True," The study meets the inclusion criteria as it involves adults with schizophrenia, examines the effects of olanzapine plasma concentrations on depressive symptoms, and is a randomized controlled pilot study."
True," The study meets the inclusion criteria as it examines the efficacy of an atypical neuroleptic (risperidone) in reducing craving and relapses in individuals with schizophrenia and cocaine dependence, which is within the scope of the review."
False," The study population (Parkinson's disease patients with drug-induced hallucinations) does not match the specified inclusion criteria (schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia)."
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia and schizoaffective disorder, whereas the review paper includes a broader range of patient populations."
True,"<This study meets all inclusion criteria, including the population (ultra-high risk of psychosis), interventions (needs-based and specific preventive intervention), and study design (randomized controlled trial), and reports on relevant outcomes (progression to first-episode psychosis)."
False,<the article does not meet the inclusion criteria as it is a review paper discussing the use of antipsychotic polypharmacy and does not present original research data on the effectiveness and harms of antipsychotic medications in specific patient populations>.
False," The article does not meet the inclusion criteria as it is a review of the literature on antipsychotic combination therapy in schizophrenia, but it does not specifically focus on the population of adults with schizophrenia."
False," The article does not meet the inclusion criteria as it does not focus on maintenance therapy in schizophrenia, but rather provides a critical comment on the rationale and feasibility of intermittent targeted therapy as an alternative treatment strategy."
False," The study population and interventions do not match the specified inclusion criteria, as the study focuses on new drugs with novel therapeutic characteristics in general, not specifically on the listed medications and patient populations."
False," The article is about the cardiac risks associated with neuroleptic medications, which is not relevant to the review's focus on the effectiveness and harms of specific antipsychotic medications in various patient populations."
False," The article does not focus on the effectiveness or harms of atypical antipsychotic agents in the specified patient populations, but rather examines trends in their use and prescribing practices."
True," The article meets all the inclusion criteria, including the population of interest (patients with acute relapse of schizophrenia or schizoaffective disorder), the intervention (aripiprazole), and the study design (randomized controlled trials)."
False," The article's focus is on the pharmacological treatment of schizophrenia, but it does not specify that the study population is limited to adults (age 18 years and older) with a DSM III-R or DSM-IV diagnosis of schizophrenia, including other psychotic disorders."
False,"<The article does not meet the inclusion criteria as it is not related to the specified patient populations or interventions, and it does not report on the effectiveness or harms of a specific treatment for a psychiatric disorder or dementia.>"
False, The study population and interventions/outcomes of interest do not match the specified criteria for the review.
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effects of antipsychotic treatment on prepulse inhibition of the startle response in drug-naive first-episode schizophrenic patients.
False," The article is a letter to the editor and does not meet the inclusion criteria for a randomized controlled trial, systematic review, or comparative observational study."
True," The study meets all inclusion criteria, including the diagnosis of first-episode schizophrenia, the focus on treatment outcome, and the use of a randomized controlled trial design."
True," The study meets all the inclusion criteria, including the population (schizophrenia patients), interventions (antipsychotic treatment), and study design (randomized-controlled trial), and the outcomes of interest (neurochemical changes and clinical response to treatment)."
True," The study meets all inclusion criteria, including being a randomized controlled trial (implied by the mention of groups receiving different antipsychotics) examining the effectiveness of antipsychotic medications in schizophrenia, which is the focus of the review."
False," The study population does not match the inclusion criteria as it includes only patients with Huntington's disease, whereas the review includes patients with schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) in the specified patient populations."
True," The study meets all the inclusion criteria, including a diagnosis of schizophrenia, a randomized controlled trial design, and a focus on the effectiveness of melperone on cognitive function."
False," The study did not involve a randomized controlled trial, but rather an open-labeled trial, which does not meet the inclusion criteria."
False," The study population is patients with schizophrenia, which is included in the review, but the intervention is amoxapine, which is not one of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone)."
True," The study meets the inclusion criteria as it examines the effects of clozapine treatment on serum glucose and lipid measures, and the population studied (individuals with schizophrenia or schizoaffective disorder) is within the scope of the review."
False," The article is a clinical orientated review article, not a study, and does not report on the effects of sulpiride and haloperidol on QTc interval prolongation."
False," The study population does not match the specified inclusion criteria, as it only includes adults with schizophrenia or schizoaffective disorder, whereas the review includes a broader range of diagnoses and age groups."
False," The study population does not match the specified criteria, as it only includes first-episode patients with schizophrenia, whereas the review paper includes patients with various psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and dementia."
True," The study meets all the inclusion criteria, including the population of interest (patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia), the interventions (novel antipsychotics), and the outcomes (effects on glucose and lipid levels)."
True," The study meets the inclusion criteria as it involves a randomized controlled trial of risperidone in first-episode, acutely psychotic patients, examining the efficacy of two different doses of the medication."
True," The study meets all the inclusion criteria, including the population of interest (psychosis patients), the interventions (risperidone, olanzapine, clozapine, and conventional antipsychotics), and the outcomes (risk of type 2 diabetes)."
False," The study does not meet the inclusion criteria for the review as it is an open-label prospective trial, not a randomized controlled trial or a comparative observational study."
False," The study population does not meet the inclusion criteria as it only includes individuals with schizophrenia, whereas the review includes a broader range of psychiatric disorders."
False," The study population does not match the inclusion criteria, as it only includes patients with treated schizophrenia, whereas the review includes patients with various psychiatric conditions, including schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders."
True," The study includes adults with schizophrenia, which is one of the specified populations of interest, and examines the effects of classical and atypical neuroleptics on bone mineral density, which is a relevant outcome."
True," The study examines the usefulness of population pharmacokinetics coupled with electronic compliance monitoring in evaluating consistency of exposure to pharmacotherapy, which is a relevant topic for the review."
False," The article does not meet the inclusion criteria as it is about the use of antiepileptic drugs in dermatology, whereas the review is focused on the effectiveness and safety of antipsychotic medications in various psychiatric conditions."
False," The study's population does not match the inclusion criteria, as it only includes adults with treatment-refractory schizophrenia, whereas the review includes a broader range of populations (schizophrenia, bipolar disorder, major depressive disorder, etc.)."
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia, uses quetiapine as an intervention, and examines effectiveness outcomes such as symptom response and adherence."
False," The study population does not match the inclusion criteria, as it includes patients with Tourette's disorder, which is not a specified diagnosis in the inclusion criteria."
True," The study meets all the inclusion criteria, including the population (elderly chronic schizophrenia patients), interventions (olanzapine and haloperidol), and outcomes (mortality, quality of life, functional capacity, hospitalization, emergency department visits, efficacy as measured by symptom response, adherence, persistence, and caregiver burden) of interest."
True," The study meets all the inclusion criteria, as it examines the association between atypical antipsychotics and glucose intolerance, and includes adults and adolescents with schizophrenia, bipolar disorder, and other psychiatric conditions."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of amisulpride in patients with acute exacerbation of schizophrenia, which is within the scope of the review's focus on schizophrenia and other psychotic disorders."
True," The study examines the relationship between Theory of Mind and clinical and social functioning in patients with schizophrenia, which aligns with the inclusion criteria of the review paper."
True," The article meets all the inclusion criteria, including the population (patients with schizophrenia), interventions (quetiapine and haloperidol), outcomes (cost-effectiveness, response rate, tolerability, and relapse rates), and study design (randomized controlled trial and economic analysis)."
False," The study does not meet the inclusion criteria as it involves healthy elderly subjects, not patients with schizophrenia, bipolar disorder, or other psychiatric conditions, and it does not examine the effectiveness or harms of a specific antipsychotic medication."
True," The study meets all inclusion criteria, including a randomized controlled design, evaluation of atypical antipsychotics in patients with schizophrenia, and assessment of effectiveness outcomes."
False," The study population (patients with parkinsonism) does not match the specified inclusion criteria (schizophrenia, bipolar disorder, major depressive disorder, etc.)."
False," The study population of the paper does not match the inclusion criteria as it only includes adults treated with antipsychotics, whereas the review includes a broader range of patient populations and interventions."
True," The study meets the inclusion criteria as it examines the cognitive functioning of individuals with first episode schizophrenia spectrum psychosis, a population of interest, and uses a comprehensive set of cognitive tests to assess changes in cognitive functioning over a 1-year period."
False," The study population does not match the inclusion criteria as it only includes adults with essential tremor, which is not one of the specified patient populations."
False," The study population does not match the inclusion criteria, as it specifically targets adults with behavioral and psychological symptoms of dementia, whereas the inclusion criteria are more general and include a broader range of psychiatric conditions."
True," The study focuses on the efficacy and safety of aripiprazole, a medication included in the review's scope, and examines its effects on various patient populations, including those with schizophrenia, bipolar disorder, and dementia, which are also included in the review's scope."
False," The study does not focus on the effects of psychotropic drugs on schizophrenia, but rather on the plasma levels of interleukin-12 in psychiatric patients, including those with major depression and bipolar mania."
True," The study meets all the inclusion criteria, as it is a randomized controlled trial examining the effectiveness of gabapentin augmentation therapy in bipolar depression, which is a relevant condition for this review."
False," The study population does not match the specified criteria, as the study only includes adults and adolescents with bipolar disorder, whereas the review includes children and adolescents with various diagnoses."
True," The study meets all inclusion criteria, including the diagnosis of rapid cycling bipolar disorder, the use of quetiapine as an intervention, and the measurement of effectiveness outcomes such as symptom response and hospitalization."
False," The study population specified in the inclusion criteria is adults and adolescents with various psychiatric conditions, which does not match the title's focus on children with autism."
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of risperidone in treating psychotic symptoms associated with chronic PTSD, which is a relevant condition for this review."
True," The study meets all the inclusion criteria as it involves patients with schizophrenia, assesses the effectiveness of olanzapine and haloperidol, and uses a randomized controlled trial design."
False, The abstract does not mention a specific intervention (antipsychotic medication) and instead focuses on the moderators of placebo response in clinical trials.
True," The study meets the inclusion criteria as it involves a randomized controlled trial in adults with schizophrenia, and it examines the effectiveness of combination therapy with divalproex and an antipsychotic agent."
False," The study does not meet the inclusion criteria because it does not focus on the effectiveness or harms of antipsychotic medications in the specified patient populations, but rather on the potential cardiotoxicity of these medications as assessed by heart rate variability."
False," The study population in this paper does not match the inclusion criteria, as it specifically focuses on adults with social anxiety disorder, whereas the review paper is focused on a broader range of psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder."
True," The study meets all inclusion criteria, including the population of interest (adults with schizophrenia), interventions (newer generation antipsychotics), and outcomes (efficacy and side-effect profiles)."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of quetiapine and haloperidol as interventions, and the measurement of prolactin levels as an outcome of interest."
True," The study meets all the inclusion criteria, including the focus on adults and adolescents with schizophrenia, the use of a decision analytic model, and the evaluation of the cost-effectiveness of olanzapine compared to haloperidol and risperidone."
False," The study does not meet the inclusion criteria as it is about rapid-cycling bipolar disorder, which is not one of the specified conditions for the review."
True," The study meets all the inclusion criteria as it is a randomized controlled trial that examines the effectiveness of olanzapine compared to placebo in treating bipolar mania, which is one of the specified patient populations."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of olanzapine in patients with bipolar I disorder with a history of rapid cycling, and reports on efficacy and adverse effects."
False," The study does not focus on adults (age 18 years and older) with a DSM III-R or DSM-IV diagnosis of schizophrenia, including other psychotic disorders, or bipolar disorder, which are the specific populations of interest for this review."
True," The study focuses on the application of molecular imaging techniques in the study of schizophrenia, which matches the specified inclusion criteria."
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of clozapine in preventing suicide attempts in patients with schizophrenia and schizoaffective disorder.
False," The study does not meet the inclusion criteria because it is an observational study examining the routine use of second-generation antipsychotics in Italy, rather than a randomized controlled trial or comparative observational study examining the effectiveness or harms of the medications."
False," The study population does not match the inclusion criteria as it only includes adults (age 18 years and older) with bipolar disorder and cocaine dependence, whereas the review includes a broader range of age groups and psychiatric conditions."
True, The study meets all the inclusion criteria as it examines the risk of diabetes in adults and adolescents with schizophrenia and bipolar disorder who are treated with olanzapine or risperidone.
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with bipolar disorder, whereas the review is focused on adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
False," The study does not meet the inclusion criteria as it does not examine the relationship between improved adherence or persistence and improved outcomes, and it does not examine the relationship between quetiapine and risperidone in the specified patient populations."
False," The study does not include a randomized controlled trial, but rather an open study, which does not meet the inclusion criteria."
True," The study meets the inclusion criteria as it involves a randomized controlled trial of risperidone in patients with schizophrenia, which is one of the interventions included in the review."
False," The title and abstract do not mention schizophrenia or cocaine abuse as the primary focus, but rather as a comorbid condition, and the article appears to be a letter to the editor rather than a research study."
False,<The article does not match the specified population (adults and adolescents with schizoaffective disorder) and does not report on the effectiveness or harms of a specific medication or intervention.>
False," The review paper's focus is on schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, which does not match the inclusion criteria of adults with cognitive disorders such as Alzheimer's disease."
False," The study population does not match the inclusion criteria, as it only includes adults (combat veterans) with posttraumatic stress disorder (PTSD), whereas the review focuses on various psychiatric disorders and populations."
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, and the population of interest is patients with inadequate response to selective serotonin reuptake inhibitors, which is not within the specified population of adults with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
True," The study meets all the inclusion criteria, including the population of interest (children and adolescents with childhood-onset schizophrenia), the intervention (clozapine), and the outcomes (effectiveness and adverse effects)."
True," The study meets all inclusion criteria, including the population (treatment-resistant schizophrenic subjects), interventions (clozapine), and outcomes (clinical response and brain metabolism) of interest."
False," The study is not a randomized controlled trial, but rather a discussion of previous studies and their methodological limitations."
True," The study meets the inclusion criteria as it examines the prevalence of impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia, which is a relevant population for the review."
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effects of atypical antipsychotics on glucose and cholesterol levels in patients with schizophrenia.
True,"<The study meets all inclusion criteria, including the population (patients with schizophrenia), intervention (olanzapine with reboxetine), and outcome (weight gain) of interest, and is a randomized controlled trial, which is the highest level of evidence included in the review.>"
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of olanzapine or haloperidol, and the assessment of subjective experience and D2 receptor occupancy."
False," The study population does not match the specified age range for inclusion in the review, as the study includes patients 13 years and older, but the review specifies including children under 13 years."
False," The article's title and abstract suggest that the paper is focused on movement disorders in children, but the inclusion criteria provided are for a review on psychiatric disorders and their treatments, not movement disorders."
False," The article does not focus on the specified psychiatric disorders or medications, and its scope is broader, covering various disciplines of internal medicine."
False," The study population does not match the inclusion criteria as it only includes adults with Parkinson's disease psychosis, whereas the review includes a broader range of patient populations, including those with schizophrenia, bipolar disorder, and dementia."
False," The study does not meet the inclusion criteria as it focuses on nefazodone and amitriptyline/haloperidol, which are not among the interventions included in the review."
True," The study meets all the inclusion criteria, including its focus on adults and adolescents with schizophrenia, bipolar disorder, and other psychiatric conditions, and its examination of the effectiveness of various antipsychotic medications."
False," The article does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified medications in the specified patient populations, but rather critiques the concept of early intervention in schizophrenia."
False," The article's title and abstract suggest that it focuses on the effects of atypical antipsychotics on serum prolactin levels in patients with schizophrenia, but the inclusion criteria specify a broader range of patient populations and outcomes, and the article's scope does not align with the specified inclusion criteria."
False," The article is a review of aripiprazole's pharmacology and clinical use, but it does not meet the inclusion criteria as it is not a randomized controlled effectiveness trial, systematic review, or observational study examining the effectiveness or harms of aripiprazole in the specified patient populations."
False," The article does not meet the inclusion criteria because it focuses on bipolar disorder in children and adolescents, but the inclusion criteria specify that the review includes adults (age 18 years and older) and adolescents (age 13 to 17 years) with bipolar disorder, but not children under 13 years."
False," The article is a letter to the editor and does not present original research or data, but rather a commentary on a previous article."
True," The study meets all the inclusion criteria, including the population (individuals with schizophrenia, bipolar disorder, major depressive disorder, and other conditions), interventions (various antipsychotic medications), and outcomes (effectiveness and harms)."
False," The article does not meet the inclusion criteria as it does not focus on the effectiveness of aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone, which are the interventions included in the review."
True," The study meets all the inclusion criteria, including the diagnosis of first episode untreated acute schizophrenia, the use of risperidone as an intervention, and the evaluation of clinical improvement and plasma HVA levels."
False," The abstract does not mention any of the specified interventions (e.g. aripiprazole, asenapine, clozapine, etc.) or patient populations (e.g. schizophrenia, bipolar disorder, etc.) that are included in the review."
False, The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified antipsychotic medications for the specified patient populations.
True," The study meets the inclusion criteria as it is a randomized controlled trial comparing the effects of flupenthixol and risperidone on subjective quality of life in chronic schizophrenic patients, which is a relevant population for the review."
False," The study's focus on the use of atypical antipsychotics for mood stabilization in bipolar disorder does not match the specified inclusion criteria, which mention schizophrenia, major depressive disorder, and behavioral and psychological symptoms of dementia."
True,"<This study meets all the inclusion criteria as it is a randomized controlled trial investigating the efficacy, safety, and tolerability of aripiprazole in patients with schizophrenia, and it reports on effectiveness outcomes such as symptom response, adherence, and persistence, as well as harms such as adverse effects and withdrawals due to adverse events.>"
False," The article is a letter to the editor commenting on another study, rather than a primary research study, and does not meet the inclusion criteria of being a randomized controlled effectiveness trial, good quality systematic review, or comparative observational study."
False," The study does not meet the inclusion criteria as it does not involve a patient population with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
False," The study population is limited to Korean schizophrenics, which does not match the inclusion criteria of adults and adolescents with various psychiatric disorders, including schizophrenia."
False," The study does not investigate the effectiveness of aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone, which are the interventions included in this review."
False," The study population in the abstract does not match the specified inclusion criteria, as it includes patients with mood disorders and healthy controls, whereas the review is focused on patients with schizophrenia, bipolar disorder, major depressive disorder, and other specific conditions."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of depot antipsychotic medications, and the comparison of switching to oral olanzapine with continued depot medication."
False," The study population does not match the inclusion criteria, as it only includes elderly nursing-home patients with dementia, whereas the review includes a broader range of patient populations, including adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
True," The study investigates the cognitive sparing effects of atypical antipsychotics in schizophrenia patients, which is relevant to the review's inclusion criteria."
False," The study does not investigate the effectiveness or harms of antipsychotic medications, but rather the factors that influence the choice between classical and atypical agents."
True," The study meets all inclusion criteria, including the focus on adults with bipolar disorder (manic or depressive phases) and the use of olanzapine as an intervention."
False," The study population does not match the inclusion criteria, as it only includes adult combat veterans with PTSD, whereas the review includes various patient populations with different psychiatric conditions."
False," The article discusses the specificity of antimanic drugs, but the population of interest (adults with mania) does not match the inclusion criteria (schizophrenia, bipolar disorder, major depressive disorder, etc.)."
True," The study meets all inclusion criteria, including the population (patients with Parkinson's disease), intervention (quetiapine), and outcomes (psychotic symptoms, sleep disturbances, and caregiver stress), and is a randomized controlled trial."
False," The study does not involve patients at risk of being prodromally symptomatic for psychosis, which is the focus of the review."
False," The study does not meet the inclusion criteria as it focuses on patients at risk of developing psychosis, whereas the review includes patients with established diagnoses of schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
True," The study meets the inclusion criteria as it involves adults with recent-onset psychosis, specifically schizophrenia, schizoaffective disorder, and schizophreniform disorder, and examines the factor structure of the PANSS, which is a widely used instrument for measuring severe psychopathology in these populations."
False," The article does not focus on the effects of antipsychotics on sexual dysfunctions and endocrine functioning, but rather reviews the literature and presents preliminary results on this topic, and discusses the role of various factors in inducing sexual dysfunctions."
False," The study population is adults with schizophrenia and related disorders treated with olanzapine, which does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
False," The study population consists of adults with chronic schizophrenia, which does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
False," The study population does not match the inclusion criteria as it includes patients with diabetes mellitus, not those with the specified psychiatric conditions."
False," The study population in this paper does not match the inclusion criteria, as it only includes adults and adolescents with bipolar disorder, whereas the review includes a broader range of patient populations, including schizophrenia, major depressive disorder, and pervasive developmental disorders."
True,"<The study meets all inclusion criteria, including the diagnosis of schizophrenia, the use of atypical antipsychotics (risperidone and olanzapine), and the measurement of simple reaction time as an effectiveness outcome.>"
True, The study meets the inclusion criteria as it is a randomized controlled trial comparing the dropout rates and response between olanzapine and risperidone in patients with schizophrenia.
False," The study population specified in the abstract (schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia) does not match the inclusion criteria (schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, as well as pervasive developmental disorders and disruptive behavior disorders in children and adolescents)."
False," The study population does not match the inclusion criteria as it specifically mentions patients with schizophrenia or schizoaffective disorder at high risk for suicide, whereas the inclusion criteria specify a broader range of diagnoses, including bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of ziprasidone in the treatment of acute bipolar mania, which is within the scope of the review."
False," The study population of moderate to severe Alzheimer's disease does not match the specified inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
True," The study meets all the inclusion criteria, including the population (treatment-resistant schizophrenia), intervention (high-dose olanzapine), and study design (case series)."
False," The study does not meet the inclusion criteria as it involves patients with dementia of the Alzheimer's type, not the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, etc.)."
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effects of an anticholinergic drug (procyclidine) on prepulse inhibition in patients with schizophrenia.
False,"<The study is not focused on a population with a DSM-III-R or DSM-IV diagnosis of schizophrenia, bipolar disorder, major depressive disorder, or other specified disorders, and does not examine the effectiveness or harms of antipsychotic medications in these populations.>"
False," The study population specified in the abstract (adults with bipolar disorder, mania) does not match the inclusion criteria (which includes adults with schizophrenia, bipolar disorder, major depressive disorder, and other conditions)."
False," The article's focus is on treatment options for bipolar depression, which does not match the specified inclusion criteria of schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders."
True," The study meets the inclusion criteria as it is a randomized, double-blind, placebo-controlled trial examining the efficacy and safety of risperidone in patients with Tourette syndrome, which is a condition included in the review."
False," The article does not match the specified inclusion criteria as it does not focus on the effectiveness of specific medications for the listed psychiatric disorders, but rather reports on new drug launches in the United States."
True," The article meets all the inclusion criteria, discussing cognitive function in schizophrenia and the effectiveness of atypical antipsychotics in improving cognitive impairments."
False," The article's focus on the metabolic brain disorder aspect of schizophrenia does not match the specified inclusion criteria, which focus on pharmacological interventions and their effectiveness outcomes."
False," The study does not meet the inclusion criteria as it focuses on late-life psychosis and schizophrenia, whereas the review is focused on a broader range of psychiatric disorders and populations."
False," The article does not meet the inclusion criteria as it does not specifically focus on the pharmacotherapy of schizophrenia, but rather discusses the evolving pharmacotherapy of schizophrenia in general."
False, The article does not meet the inclusion criteria as it does not focus on a specific population (schizophrenia) but rather discusses the broader topic of adverse effects of antipsychotic medications.
False," The study population does not match the inclusion criteria as it includes adults with thought or mood disorders, but the disorders mentioned are not specified as schizophrenia, bipolar disorder, or major depressive disorder."
True, The study meets all the inclusion criteria as it is a head-to-head randomized controlled trial comparing the efficacy and safety of amisulpride and risperidone in patients with schizophrenia.
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of electroconvulsive therapy (ECT) in treatment-resistant schizophrenia, which is a population of interest in this review."
True, The study meets the inclusion criteria as it is a randomized controlled trial (RCT) comparing the safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
False," The study is not a randomized controlled trial, but rather a before-after study with a small sample size, which does not meet the inclusion criteria for the review."
False," The study population does not match the specified inclusion criteria, as it includes patients with dementia with Lewy bodies, which is not a specified diagnosis for inclusion in the review."
True," The study meets all the inclusion criteria, including the population of interest (patients with schizophrenia), the type of study (randomized controlled trial), and the outcomes of interest (suicide and attempted suicide)."
False, The article does not focus on the effectiveness and tolerability of aripiprazole in the specified patient populations.
True," The study meets all the inclusion criteria, including the population (treatment-naive first-episode schizophrenia patients), interventions (clozapine and chlorpromazine), and outcomes (efficacy and safety)."
False," The study population in this paper does not match the inclusion criteria, as it only includes adults with bipolar disorder, whereas the review paper includes a broader range of psychiatric disorders."
True," The study meets all the inclusion criteria as it involves adults with bipolar disorder, a randomized controlled trial, and compares the effectiveness and cost of two treatments (divalproex and olanzapine)."
False, The abstract does not mention the specific interventions or outcomes of interest for the review.
True," The study meets the inclusion criteria as it examines the effectiveness and side effects of three antipsychotic medications (olanzapine, risperidone, and haloperidol) in adolescents with schizophrenia."
False," The study population specified in the inclusion criteria does not match the population mentioned in the title and abstract, which appears to be focused on lithium augmentation in treatment-refractory unipolar depression."
True," The article appears to be relevant to the review's focus on pharmacological treatment in schizophrenia, and its abstract mentions modern concepts of treatment that include multidirectional therapeutic actions."
True," The study meets the inclusion criteria as it examines the effect of olanzapine treatment on cognitive functions in patients with schizophrenia, which is a relevant population for the review, and uses a study design that is included in the review criteria."
False," The study population does not match the inclusion criteria as it only includes patients with schizophrenia treated with olanzapine, whereas the review paper includes a broader range of patient populations and interventions."
False," The study population is limited to adults with schizophrenia or schizoaffective disorder, which does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, and other specified disorders."
False,"<The study population is adults with schizophrenia, whereas the inclusion criteria specify a wide range of patient populations, including children and adolescents with various psychiatric conditions, and older adults with dementia, which is not the focus of this study.>"
False," The study population is not representative of the target population specified in the review (individuals with first episode psychosis), as the study only included patients from a controlled trial and a cohort study, and not individuals from routine clinical practice."
True, The study meets the inclusion criteria as it is a randomized controlled trial comparing the efficacy and safety of olanzapine and risperidone in patients with schizophrenia.
False," The title and abstract do not mention the inclusion criteria of the review, specifically the disorders and populations of interest."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of a randomized controlled trial design, and the measurement of antipsychotic efficacy using the BPRS and PANSS scales."
False," The study population includes patients with severe mental illness, but it does not specifically focus on patients with schizophrenia, bipolar disorder, or other conditions listed in the inclusion criteria."
False," The study does not meet the inclusion criteria as it focuses on a specific population (schizophrenia and schizoaffective disorders) and does not include the specified interventions (e.g. aripiprazole, asenapine) or effectiveness outcomes (e.g. mortality, quality of life)."
False," The study population specified in the inclusion criteria does not match the population mentioned in the abstract, which is bipolar disorder."
False," The article does not focus on antipsychotic drugs, but rather discusses the advantages and disadvantages of placebo-controlled and active-control trials in general, and proposes the use of active-control noninferiority trials for demonstrating noninferiority of antipsychotic efficacy."
False," The study does not meet the inclusion criteria because it is a systematic review and meta-analysis comparing new generation antipsychotics with low-potency conventional antipsychotics, but the population of interest is not specified as adults (18 years and older) and adolescents (13-17 years) with a DSM III-R or DSM-IV diagnosis of schizophrenia, bipolar disorder, or other psychiatric conditions."
True," The study meets all inclusion criteria, including the population (patients with schizophrenia), intervention (quetiapine and haloperidol), and outcomes (agitation and hostility scores)."
True," The study meets all the inclusion criteria, including the population (stable outpatients with DSM-IV schizophrenia), intervention (quetiapine vs conventional antipsychotics), and outcomes (cognitive and functional measures)."
True,"<The study meets all the inclusion criteria, including the population (stable outpatients with schizophrenia), intervention (switching to ziprasidone), and outcome (symptom improvements and tolerability) of interest, and is a randomized controlled trial, which is the highest level of evidence included in the review.>"
False, The study does not meet the inclusion criteria as it is a cost analysis study and not a randomized controlled trial or a comparative observational study examining the relationship between improved adherence or persistence and improved outcomes.
False," The study population includes patients with schizophrenia, but the sample size is limited to 56 patients, and the study does not compare the interventions to a placebo or conventional antipsychotics."
True," The study meets all the inclusion criteria, as it examines the effectiveness of clozapine in patients with schizophrenia, and it is a randomized controlled trial that investigates the relationship between improved adherence or persistence and improved outcomes."
False," The study population is older adults with behavioral and psychological symptoms of dementia, but the interventions and outcomes of interest do not match the specified criteria."
True," The study meets all inclusion criteria, including a focus on adults with schizophrenia, use of atypical antipsychotics (risperidone or olanzapine), and examination of effectiveness outcomes such as quality of life and symptom response."
False," The study focuses on the efficacy of nefazodone in treating neuroleptic-induced extrapyramidal side effects, which is not within the scope of the review, which focuses on the effectiveness of atypical antipsychotics in treating various psychiatric disorders."
True," The study meets all inclusion criteria, including the population of interest (patients with schizophrenia), interventions (long-acting injectable risperidone), and outcomes (efficacy and safety)."
True," The study meets all inclusion criteria, including the diagnosis of treatment-resistant schizophrenia, the use of typical antipsychotics and clozapine, and the examination of symptom response and effect sizes."
True," The study meets all the inclusion criteria, including the population (first-episode schizophrenia), interventions (olanzapine), outcomes (effectiveness, safety, quality of life), and study design (naturalistic study)."
False," The study population is children and adolescents with bipolar disorder, which does not match the specified population of adults (age 18 years and older) and adolescents (age 13 to 17 years) and children (under 13 years) with bipolar disorder."
False," The study population specified in the inclusion criteria does not match the population described in the abstract, as the abstract mentions bipolar disorder, but the inclusion criteria specify schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
False," The study does not meet the inclusion criteria because it only examines the cost-effectiveness of three specific medications (risperidone, olanzapine, and conventional antipsychotics) and does not include the interventions (medications) specified in the review (e.g. aripiprazole, asenapine, etc.)."
True," The article meets all inclusion criteria as it presents an analysis of the costs and benefits of switching from typical to atypical antipsychotic drugs for schizophrenia, using data from published studies, and estimates outcomes such as health care costs, symptom days, and employment days."
True," The study meets all the inclusion criteria, including the focus on adults and adolescents with schizophrenia, and the inclusion of second-generation antipsychotics as an intervention."
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia, whereas the review includes a broader range of patient populations."
False," The article's focus is on the classification and treatment of tardive syndromes, which does not match the specified inclusion criteria of reviewing interventions for various psychiatric and neurodevelopmental disorders."
False, The article does not match the inclusion criteria as it does not specifically focus on the use of atypical antipsychotics in traumatic brain injury (TBI) but rather discusses their use in various psychiatric conditions.
True," The study meets all inclusion criteria, including the population (agitated patients with schizophrenia, bipolar mania, or dementia), intervention (intramuscular olanzapine), and outcomes (calming effects, sedation, and adverse events), and is a randomized controlled trial."
False," The study population is adults with bipolar disorder, which does not match the inclusion criteria for schizophrenia, including other psychotic disorders."
False," The study objective is to explore the clinical characteristics of hyperglycemia in patients treated with risperidone, but it does not meet the inclusion criteria as it is a pharmacovigilance study and not a randomized controlled trial, good-quality systematic review, or comparative observational study examining the effectiveness or harms of risperidone in the specified patient populations."
False," The study population is limited to Texas Medicaid clients, which does not meet the inclusion criteria of adults (age 18 years and older) with a DSM III-R or DSM-IV diagnosis of schizophrenia."
False," The article does not meet the inclusion criteria as it is not a study on the effectiveness or harms of antipsychotic medications, but rather a review of dose equivalence estimates for various atypical antipsychotics."
False," The study population is not adults with schizophrenia or other psychotic disorders, but rather older adults with behavioral and psychological symptoms of dementia."
False," The study population does not match the inclusion criteria as it only includes hospitalized schizophrenic and schizoaffective patients, whereas the review includes a broader range of patient populations."
True," The study meets all inclusion criteria, including a randomized controlled trial design, a focus on schizophrenia, and a comparison of mirtazapine with a placebo."
True," The study meets all the inclusion criteria, including the population (adults with schizophrenia), intervention (new-generation antipsychotic drugs), and outcomes (relapse prevention)."
True," The study meets the inclusion criteria as it is a randomized controlled trial comparing the effectiveness of olanzapine and divalproex for the treatment of acute mania and maintenance of remission in bipolar disorder, which is a relevant population for this review."
False," The study does not meet the inclusion criteria because it does not focus on the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia) and does not examine the specified outcomes (mortality, quality of life, functional capacity, etc.)."
False," The article does not meet the inclusion criteria as it does not involve patients with schizophrenia or related disorders, and the intervention is not one of the specified antipsychotics."
False," The article's focus is on clozapine's adverse effects and management, whereas the review paper's inclusion criteria specify a broad range of outcomes, including effectiveness, harms, and adherence/persistence."
False," The article does not meet the inclusion criteria as it is a review of pharmacologic management of agitation, not a review of treatments for the specified patient populations."
False,"<The study population is patients with delirium, which is not included in the specified inclusion criteria, and the study is a prospective open trial, which is not considered a high-quality study design in the specified inclusion criteria>."
False, The study population (palliative care patients) does not match the inclusion criteria (various psychiatric and neurological disorders).
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the efficacy and safety of aripiprazole in patients with schizophrenia and schizoaffective disorder, and the population and outcomes of interest align with the review's inclusion criteria."
False," The study does not examine the effectiveness or harms of olanzapine versus haloperidol in children or adolescents with pervasive developmental disorders or disruptive behavior disorders, and does not include a comparison of adherence or persistence between the two medications."
True," The study meets all the inclusion criteria, including the population (patients with schizophrenia), intervention (quetiapine), and outcome (effectiveness on depressive symptoms)."
False," The study does not meet the inclusion criteria as it is a pharmacokinetic study comparing the bioavailability of two risperidone formulations, but does not examine the effectiveness or harms of risperidone in any of the specified patient populations."
True," The study meets all the inclusion criteria as it is a randomized controlled trial examining the effectiveness of olanzapine in reducing craving for alcohol, and it includes data on the interaction between the DRD4 VNTR polymorphism and pharmacotherapy."
False," The study is a randomized controlled trial of vitamin E vs placebo, but it does not meet the inclusion criteria as it is not a trial of the specified interventions (e.g. aripiprazole, asenapine, etc.) or patient populations (e.g. schizophrenia, bipolar disorder, etc.)."
False," The study population specified in the abstract (treatment-resistant schizophrenia) does not match the inclusion criteria, which includes various psychiatric disorders and populations."
True," The study meets all the inclusion criteria, including a randomized, double-blind trial design, comparison of an atypical antipsychotic (olanzapine) with a conventional antipsychotic (haloperidol), and assessment of effectiveness and safety outcomes in patients with first-episode psychosis."
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of risperidone versus haloperidol in patients with stabilized DSM-IV schizophrenia.
True," The study meets all inclusion criteria, including the population (partially responsive outpatients with schizophrenia), interventions (clozapine and haloperidol), outcomes (symptom response, adherence, and persistence), and study design (randomized controlled trial)."
True," The article meets the inclusion criteria as it involves a patient with schizophrenia and comorbid substance abuse, and the intervention is quetiapine, which is included in the list of interventions for this review."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of antipsychotic medications in patients with schizophrenia, and it is a high-quality study with a well-defined protocol and a large sample size."
False," The article is about the development of a trial protocol for Alzheimer's disease, which does not match the inclusion criteria of focusing on schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions."
False," The study population is not specified as adults (18+ years) with schizophrenia, bipolar disorder, major depressive disorder, or dementia, which is a required inclusion criterion."
False, The article does not meet the inclusion criteria as it does not focus on a specific patient population (e.g. children under 13 years) or intervention (e.g. aripiprazole) that is relevant to the review.
True," The study meets all the inclusion criteria, as it is a prospective analysis of predictors of suicide risk in a large schizophrenic and schizoaffective population, and it examines the effectiveness of clozapine and olanzapine in decreasing the risk of suicidality."
False," The study population does not match the inclusion criteria, as the study only includes patients with the prodromal phase of schizophrenic disorders, whereas the review focuses on patients with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions."
False," The study does not meet the inclusion criteria as it is not a randomized controlled effectiveness trial, systematic review, or comparative observational study examining the relationship between improved adherence or persistence and improved outcomes."
True," The study meets all inclusion criteria, including the population (adults with schizophrenia or bipolar disorder), interventions (olanzapine), and outcomes (efficacy as measured by symptom response)."
False," The study population specified in the abstract (adults with acute mania) does not match the inclusion criteria, which specifies a broader range of psychiatric disorders and age ranges."
False," The article does not appear to be about the treatment-emergent tardive dyskinesia with quetiapine, but rather appears to be a broad review of various antipsychotics and their effects on different patient populations."
False," The study population does not match the inclusion criteria, as it includes normal subjects, not individuals with a DSM III-R or DSM-IV diagnosis of schizophrenia or other psychotic disorders."
True," The study meets all the inclusion criteria, as it is a systematic review of pharmacological treatment for negative symptoms of schizophrenia, includes relevant interventions and outcomes, and is based on high-quality study designs."
False," The study population does not match the inclusion criteria, as it specifically focuses on adults (age 18 years and older) and adolescents (age 13-17 years) with Alzheimer's disease, which is not mentioned in the inclusion criteria."
False," The study population does not match the inclusion criteria, as it only includes schizophrenia patients, whereas the review includes patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The study focuses on the frequency and severity of extrapyramidal syndrome (EPS) in patients with schizophrenia during olanzapine clinical trials, which does not meet the inclusion criteria of focusing on effectiveness outcomes such as mortality, quality of life, functional capacity, and hospitalization."
False," The study population does not match the inclusion criteria as it only includes patients with acute mania associated with bipolar disorder, whereas the review includes a broader range of patient populations."
True," The study meets all the inclusion criteria, including the diagnosis of bipolar disorder, the use of aripiprazole, and the study design as a randomized controlled trial."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of clozapine in patients with schizophrenia, and it includes the relevant population (adults and adolescents with schizophrenia) and outcome measures (symptom response, adherence, and persistence)."
False," The article is about the introduction and pharmacological effects of quetiapine, but it does not report on any outcomes of interest for the review."
True," The study meets all the inclusion criteria, including the population (patients with treatment-resistant schizophrenia), intervention (occupational therapy), and outcome measures (effectiveness of occupational therapy in improving symptoms and functional capacity)."
False," The study population is not limited to adults (age 18 years and older) with a DSM III-R or DSM-IV diagnosis of schizophrenia, but also includes adolescents and children, as well as individuals with other psychiatric conditions."
False,"<this study examines the risk of suicide in patients with bipolar disorder during treatment with lithium and divalproex, which is not within the specified inclusion criteria of schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia>."
True,"<This article meets all the inclusion criteria, as it is a systematic review of treatments for bipolar disorder, includes adults and adolescents with bipolar disorder, and discusses effectiveness and harm outcomes for various interventions.>"
False," The article is a review of a specific study, the CATIE Project, and does not report on the effectiveness or harms of a particular medication."
False," The article does not meet the inclusion criteria as it is a review on pharmacotherapy for eating disorders, not schizophrenia, bipolar disorder, or other conditions specified in the inclusion criteria."
False," The study does not involve any of the specified patient populations or interventions, and the outcomes measured are not aligned with the specified effectiveness outcomes."
False," The study does not meet the inclusion criteria as it does not focus on the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, etc.) or interventions (listed medications) and outcomes (effectiveness and harms)."
False," The study population is not adults with bipolar disorder, but rather patients with bipolar disorder, which does not match the specified population."
False," The article does not meet the inclusion criteria as it is about the use of galantamine in patients with Parkinson's disease with dementia, which is not within the scope of the review paper."
True," The study meets all inclusion criteria, including a focus on antipsychotic-induced weight gain in patients with schizophrenia, a randomized controlled design, and a relevant population and intervention."
False," The article does not meet the inclusion criteria as it is a case series review of clozapine use in pregnancy, not a randomized controlled trial, systematic review, or comparative observational study examining the effectiveness or harms of clozapine in a specific patient population."
True," The paper addresses methodological and regulatory issues relevant to clinical trials for behavioral and psychological symptoms of dementia, which matches the topic of interest."
False," The article does not match the specified inclusion criteria as it discusses the management of acute mania and does not focus on schizophrenia, which is the primary condition of interest in the specified inclusion criteria."
True,"<The study meets all the inclusion criteria, including a diagnosis of schizophrenia, a randomized controlled trial design, and an examination of effectiveness and cost outcomes.>"
False," The study population does not match the inclusion criteria as it specifically focuses on patients with Parkinson disease, which is not one of the included populations."
False," The study population specified in the title and abstract (schizophrenic patients on clozapine) does not match the inclusion criteria, which specify a broader range of psychiatric disorders, including bipolar disorder, major depressive disorder, and pervasive developmental disorders."
False," The study population specified in the abstract does not match the inclusion criteria, as it includes children under 13 years old with pervasive developmental disorders and disruptive behavior disorders, which are not specified in the inclusion criteria."
False," The study does not meet the inclusion criteria for interventions, as it only compares two neuroleptic medications (risperidone and perphenazine) and does not include the specified interventions (e.g. aripiprazole, clozapine, etc.)."
True," The study meets all the inclusion criteria, including the population (schizophrenic patients with acute symptoms), interventions (risperidone and clozapine), outcomes (antipsychotic effect and tolerance), and study design (randomized double-blind trial)."
True,"<The study meets all the inclusion criteria, as it is a randomized controlled trial examining the efficacy and safety of risperidone in the treatment of schizophrenia, which is a relevant condition for this review, and reports on relevant outcomes such as clinical improvement, side effects, and optimal dose.>"
False," The article does not meet the inclusion criteria because it does not focus on the effectiveness of antipsychotic medications in treating specific psychiatric disorders, but rather on the prediction of clinical effects of neuroleptics from animal data."
False," The study population is not limited to adults (age 18 years and older) with schizoaffective disorder, but includes a broader range of diagnoses and age groups."
True," The study meets all inclusion criteria, including the population (chronic schizophrenic patients), interventions (risperidone and haloperidol), and study design (randomized controlled trial)."
False," The article does not meet the inclusion criteria as it focuses on clozapine response in schizophrenia, but does not provide information on the effectiveness or harms of clozapine in the specified patient populations."
False," The study population is not specified as adults or adolescents with schizophrenia, but rather as patients with a wide range of psychiatric conditions, including schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
True,"<The paper reports on the efficacy and safety of risperidone in various psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder, making it relevant to the review paper's inclusion criteria.>"
False," The study is a case report, not a randomized controlled trial, systematic review, or comparative observational study."
False," The study population does not match the inclusion criteria, as it only includes adult patients with chronic schizophrenia."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia, the use of atypical antipsychotics (risperidone and clozapine), and the evaluation of effectiveness outcomes such as symptom response and adherence."
True," The article meets all the inclusion criteria, including the population (schizophrenia and other psychotic disorders), interventions (risperidone), and outcomes (efficacy and harms) of interest."
False," The study does not examine the effectiveness or harms of the included interventions in the specified patient populations, but rather focuses on the dopamine D2 receptor blockade in vivo with risperidone and remoxipride."
True," The study is about the risk-benefit assessment of risperidone in schizophrenia, which is a specific condition mentioned in the inclusion criteria."
True," The study meets all the inclusion criteria, including a randomized controlled trial design, a focus on the treatment of acute schizophrenic episodes, and the inclusion of risperidone as an intervention."
True," The study population and interventions match the specified criteria, and the review includes a broad range of effectiveness and harms outcomes."
False," The study population does not match the specified inclusion criteria, as it only includes adults and adolescents with chronic schizophrenia, whereas the review includes a broader range of patient populations (e.g., children, older adults, individuals with bipolar disorder, etc.)."
True," The study meets the inclusion criteria of focusing on adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, and examining the effectiveness and harms of various antipsychotic medications."
False," The article does not report on the effectiveness of iloperidone in any of the specified patient populations or outcomes of interest, and instead focuses on its pharmacokinetics and safety profile in healthy volunteers."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia in adults, the intervention of clozapine, and the outcome of plasma SIL-2R levels."
True,"<The study meets all inclusion criteria, including the diagnosis of schizophrenia, the use of ICI 204,636 as an atypical antipsychotic, and the assessment of efficacy and safety outcomes in a randomized controlled trial.>"
True," The study meets all inclusion criteria, including the population of interest (patients with chronic schizophrenia), the intervention (risperidone), and the study design (open-label study)."
False," The study is a case series, which is not a randomized controlled trial, comparative observational study, or systematic review, and therefore does not meet the inclusion criteria for the review."
True," The study population includes adults with schizophrenia, bipolar disorder, major depressive disorder, and older adults with dementia, which meets the inclusion criteria."
False," The study does not meet the inclusion criteria because it does not focus on the effectiveness outcomes of interest for patients with schizophrenia, such as mortality, quality of life, and functional capacity, but rather on the effect of risperidone on hostility."
False," The study does not match the specified inclusion criteria as it focuses on extrapyramidal side effects of clozapine and haloperidol, but does not evaluate the effectiveness or harms of these medications in the specified patient populations or with the specified outcomes."
False," The study does not examine the effectiveness of clozapine in patients with schizophrenia, but rather its effect on smoking behavior in patients already being treated with clozapine."
False," The article does not meet the inclusion criteria as it is a review of the use of placebos in clinical trials for acute schizophrenia, not a study on the effectiveness or harms of a specific medication for a specific population."
True," The study meets the inclusion criteria as it involves a clinical trial of clozapine in patients with refractory schizophrenia, which is one of the specified patient populations, and reports on effectiveness outcomes such as symptom response and functional capacity."
True," The study meets all the inclusion criteria, including the population (treatment-resistant patients with schizophrenia), intervention (clozapine), and outcomes (efficacy and harms), and is a randomized controlled trial."
False," The study is an open clinical trial, not a randomized controlled trial, which does not meet the inclusion criteria."
True," The article meets all the inclusion criteria, as it is a review of studies on the efficacy and tolerability of clozapine in severe mood disorders, which aligns with the specified inclusion criteria."
False," The article title and abstract do not indicate that the study focuses on the specific antipsychotic medication Seroquel (quetiapine), but rather appears to be a review of multiple antipsychotic medications."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia and the use of clozapine as an intervention, and reports on the relationship between serum concentrations of clozapine and its metabolites and leukocyte counts, which is a relevant outcome of interest."
False," The article does not match the specified inclusion criteria as it is about selective serotonin reuptake inhibitors (SSRIs) and their pharmacologic profiles, whereas the review paper appears to be focused on antipsychotics and their effectiveness outcomes."
False," The study population in the abstract does not match the inclusion criteria, as it specifically mentions ""childhood-onset schizophrenia"" and does not include adults or adolescents with schizophrenia, bipolar disorder, or other disorders."
True," The study meets all the inclusion criteria, including the focus on adolescent schizophrenic patients, the use of high-performance liquid chromatography, and the inclusion of pharmacokinetic data and dose-response relationships."
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (e.g. aripiprazole, asenapine, etc.) or patient populations (e.g. schizophrenia, bipolar disorder, etc.)."
False," The study population does not match the specified criteria, as it only includes adults with schizophrenia, whereas the review includes a broader range of populations, including children and adolescents with various diagnoses."
True,"<The study meets all the inclusion criteria: it focuses on adults with schizophrenia, includes a randomized controlled trial, and examines the relationship between clozapine serum levels and side effects, which is a relevant outcome for this review.>"
False," The article does not specifically focus on adults (age 18 years and older) and adolescents (age 13 to 17 years) with a DSM III-R or DSM-IV diagnosis of schizophrenia, which is a specified inclusion criterion."
False," The study does not meet the inclusion criteria as it is a case series of four patients and does not meet the inclusion criteria of being a randomized controlled trial, good quality systematic review, or comparative observational study."
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) in the specified patient populations."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia, the use of clozapine as an intervention, and the assessment of suicidality as an effectiveness outcome."
False," The study does not examine the effectiveness or harms of clozapine in the specified patient populations, but rather investigates EEG alterations in relation to plasma levels in patients treated with clozapine."
False," The study does not meet the inclusion criteria as it focuses on pharmacologic treatment of schizoaffective disorder, but the review paper's inclusion criteria are broader and include other psychiatric disorders and patient populations."
True," The study meets the inclusion criteria as it focuses on adolescents with schizophrenia and examines the effects of clozapine on biogenic amines, which is a relevant topic for the review."
False," The article does not meet the inclusion criteria as it is not a randomized controlled trial, systematic review, or comparative observational study examining the effectiveness of clozapine in a specific population or condition."
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing clozapine to haloperidol in patients with schizophrenia, examining the long-term effect of clozapine on neuropsychological test performance, and reports on effectiveness outcomes such as quality of life and symptom response."
False," The study is a case report of a specific patient population and does not meet the inclusion criteria of being a randomized controlled trial, good quality systematic review, or comparative observational study."
False," The study population does not match the inclusion criteria, as the study only includes DSM-III-R schizophrenic inpatients."
True," The study meets all the inclusion criteria, including the population (refractory schizophrenia patients), intervention (clozapine), and study design (prospective study)."
True," The study meets all inclusion criteria, including the population (patients with refractory bipolar disorders), intervention (clozapine), and outcome measures (hospitalization rate, affective episodes) of interest."
False," The study population consists of Parkinson's disease patients, which does not match the inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions."
False," The study population specified in the abstract (e.g. adults with schizophrenia, bipolar disorder, etc.) does not match the inclusion criteria for the review, which includes children and adolescents with pervasive developmental disorders and disruptive behavior disorders."
False," The study does not meet the inclusion criteria for interventions, as it involves electroconvulsive therapy (ECT) rather than one of the specified antipsychotic medications."
True," The study includes adult patients with schizophrenia, which is within the specified age range and diagnosis criteria."
True," The study meets all the inclusion criteria, including the specific population (schizophrenic and schizoaffective patients), intervention (clozapine), and outcome (response to treatment)."
False," The study does not focus on the effect of clozapine on neurological signs, but rather uses the examination of these signs as a mechanism to evaluate the relationship between extrapyramidal symptoms and tardive dyskinesia and psychopathology."
False, The study does not meet the inclusion criteria for the review as it does not involve a randomized controlled trial or a comparative observational study examining the relationship between improved adherence or persistence and improved outcomes.
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of clozapine as an intervention, and the assessment of clinical response and plasma clozapine concentrations as effectiveness outcomes."
True," The article meets all the inclusion criteria, including the population of interest (schizophrenia), intervention (clozapine), and study design (preclinical and clinical studies)."
False," The study population is limited to adults and adolescents with schizophrenia, bipolar disorder, and other conditions, which does not align with the specified inclusion criteria that include children and adolescents with pervasive developmental disorders and disruptive behavior disorders."
False," The study population is treatment-resistant schizophrenia patients, which is a specific subgroup of the broader schizophrenia population included in the review, and the study design is a randomized controlled trial, but the review criteria do not specify the inclusion of RCTs for this specific subgroup."
False," The article does not meet the inclusion criteria as it is a study on the immunogenic mechanism of clozapine-induced cytotoxicity, which is not related to the effectiveness or harms of the included medications in the specified patient populations."
True," The study meets all the inclusion criteria, including the population of interest (patients with chronic schizophrenia), the intervention (clozapine), and the outcomes (weight gain, treatment response, and risk factors)."
False," The study does not focus on the effectiveness or harms of clozapine, but rather discusses the factors that influence response to neuroleptic drugs in general, including pharmacogenetic and pharmacodynamic differences."
False, The study does not examine the effectiveness or harms of clozapine in any of the specified patient populations or outcomes.
False," The study population is not specified, but it appears to be a cohort study of clozapine-treated patients, which does not meet the inclusion criteria of being a randomized controlled trial, good-quality systematic review, or comparative observational study examining the relationship between improved adherence or persistence and improved outcomes."
True," The study meets all the inclusion criteria, including the focus on adults with schizophrenia, the use of clozapine as an intervention, and the assessment of cognitive function as an effectiveness outcome."
False," The study population is treatment-refractory mood disorders, which is not one of the specified populations of interest (schizophrenia, bipolar disorder, major depressive disorder, etc.)."
True," The study meets all the inclusion criteria, including the population (adolescents with childhood-onset schizophrenia), interventions (clozapine and haloperidol), outcomes (clinical benefit, plasma concentrations), and study design (randomized controlled trial)."
False," The article does not report on any of the specified interventions (e.g. aripipride, asenapine, etc.) but rather on the clinical action of Remoxipride."
True," The study meets all the inclusion criteria, as it involves a randomized controlled trial of clozapine, a medication included in the review, in patients with schizophrenia, one of the target populations, and examines outcomes such as symptom response, adherence, and persistence."
False," The study does not meet the inclusion criteria as it only focuses on the incidence of seizures in patients taking clozapine, and does not provide data on the effectiveness or harms of clozapine in the treatment of schizophrenia or other psychiatric conditions."
False," The study population does not match the inclusion criteria, as it focuses on dementia patients, whereas the review paper is interested in adults with schizophrenia, bipolar disorder, major depressive disorder, and children with pervasive developmental disorders and disruptive behavior disorders."
False," The study only examined the pharmacokinetics of clozapine and desmethylclozapine in a small sample of male chronic patients, and did not assess any of the specified outcomes or populations."
True," The article meets all the inclusion criteria, including the population of interest (adults and adolescents with various psychiatric disorders), interventions (various antipsychotic medications), and outcomes (effectiveness and harms)."
False," The study population does not match the inclusion criteria as it only includes patients with schizophrenia, whereas the review includes a broader range of psychiatric conditions."
True," The study meets the inclusion criteria as it examines the effects of a Medicaid policy change on the use of psychotropic agents and acute mental health services in patients with schizophrenia, and it uses a rigorous study design (interrupted time-series regression analysis) to estimate the effects of the policy change."
False," The study population is a state hospital, which does not match the specified inclusion criteria of adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions."
False," The study population is schizophrenic inpatients, which does not match the inclusion criteria of adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions."
True," The study meets all the inclusion criteria, including the population (chronic schizophrenic outpatients), intervention (clozapine), and outcome measures (clinical responses, relapses, hospitalizations, symptomatology, and functioning)."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia and the use of clozapine as an intervention, and the outcomes of interest such as symptom response and adverse effects are relevant to the review."
False," The study only examined the response to clozapine in 10 patients with treatment-refractory first-episode schizophrenia, which does not meet the inclusion criteria of examining multiple patient populations with various diagnoses."
False," The study population is not limited to adults with schizophrenia, bipolar disorder, or major depressive disorder, but also includes adolescents and children with various psychiatric conditions, which does not meet the specified inclusion criteria."
False," The study only includes adults and adolescents with schizophrenia, whereas the review includes children and adolescents with pervasive developmental disorders and disruptive behavior disorders."
False, The title and abstract do not mention anything related to the inclusion criteria of the review paper.
False," The study population consists of adult schizophrenic patients, which does not match the inclusion criteria of children, adolescents, and older adults with various diagnoses."
False," The study population does not match the specified criteria as it only includes psychotic patients, whereas the review is focused on a broader range of patient populations, including those with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
True, The study meets the inclusion criteria as it involves adults with schizophrenia and examines the effectiveness of clozapine.
False," The article does not focus on the effectiveness of clozapine in patients with schizophrenia, but rather discusses the potential strategies for augmentation of neuroleptic drugs in treatment-resistant patients."
True,"<study examined the course of treatment response in first-episode and chronic schizophrenia, which matches the inclusion criteria of the review paper.>"
True," The study meets all the inclusion criteria, as it involves a randomized controlled trial comparing the side effects of risperidone and clozapine in patients with schizophrenia or schizoaffective disorder, and the outcomes of interest (side effect profiles) are relevant to the review."
False," The study population in the abstract does not match the specified inclusion criteria, which include adults (18+ years) with schizophrenia, bipolar disorder, or major depressive disorder, among others, whereas the study population consists of inpatients with schizophrenia or schizo-affective illness."
True," The study meets all the inclusion criteria, including the population (schizophrenia patients), interventions (clozapine and haloperidol), outcomes (weight gain and clinical improvement), and study design (randomized controlled trial)."
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, examines the relationship between a genetic polymorphism and the disorder, and reports on clinical response to treatment."
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, examines the effectiveness of clozapine in maintenance therapy, and includes randomized controlled trials."
True," The study meets all the inclusion criteria, including population, interventions, outcomes, and study design."
False," The study does not investigate the effectiveness or harms of clozapine in the specified populations, but rather the association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine."
False,"<The study population is not limited to adults (age 18 years and older) with schizophrenia or other psychotic disorders, but also includes state hospital patients with various diagnoses, and does not focus on the specified age groups or diagnoses listed in the inclusion criteria>."
False,"<The study only investigates the efficacy and safety of ICI 204,636 in adults with schizophrenia, whereas the review includes a broader range of patient populations and outcomes.>"
True," The study appears to meet all the specified inclusion criteria, including population, interventions, outcomes, and study designs."
False," The study population consists of hospital in-patients with schizophrenia, schizoaffective and bipolar disorders, which does not match the inclusion criteria of adults with schizophrenia, including other psychotic disorders, or adults with bipolar disorder."
False," The study does not meet the inclusion criteria because it is an open-label clinical trial, not a randomized controlled trial, and it does not examine the effectiveness or harms of one of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone) in one of the specified patient populations."
False," The study population specified in the abstract does not match the inclusion criteria, as it only includes schizophrenic patients, whereas the inclusion criteria specify a broader range of psychiatric disorders."
False," The study does not meet the inclusion criteria as it does not involve a randomized controlled trial, and the population studied is treatment-resistant patients with schizophrenia, which is not specified in the inclusion criteria."
False," The article does not meet the inclusion criteria as it is not a randomized controlled trial, good quality systematic review, or comparative observational study examining the effectiveness and harms of antipsychotic medications in the specified patient populations."
False," The study population does not match the inclusion criteria, as it only includes patients with tardive dyskinesia, whereas the review is focused on various psychiatric disorders and their treatment with specific medications."
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the relationship between a genetic polymorphism and response to clozapine in patients with schizophrenia.
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of risperidone in treating negative symptoms of schizophrenia, a population of interest for this review."
True," The study focuses on the efficacy and safety of clozapine, which is one of the interventions included in the review."
True," The study meets all inclusion criteria, including a focus on the efficacy and safety of risperidone in persons with schizophrenia, and includes relevant study design and population criteria."
False," The study population specified in the inclusion criteria for the review paper does not match the population of the current study, which focuses on children with developmental disabilities."
True," The study meets all the inclusion criteria, including the population (chronic schizophrenia patients), intervention (neuroleptic treatment), and outcome (metabolic changes measured by 1H MR spectroscopy) of interest."
True," The study meets all the inclusion criteria, including the population of interest (adults with schizophrenia), the intervention (olanzapine), and the outcomes (symptom response, adverse effects)."
False," The article's focus is on treatment-resistant schizophrenic patients, but it does not explicitly state that it includes patients with other psychiatric disorders, which is a requirement for inclusion in the review."
False," The study population specified in the title and abstract (adults and adolescents with various psychiatric conditions) does not match the inclusion criteria, which include children under 13 years with pervasive developmental disorders."
False," The study does not investigate the effectiveness or harms of the specified antipsychotic medications, but rather explores the relationship between free radical scavenging enzyme activity and clozapine-induced agranulocytosis."
True," The study meets all inclusion criteria, including the population (schizophrenic patients), interventions (risperidone, haloperidol, and methotrimeprazine), and outcomes (clinical improvement, symptom response, and adverse effects) of interest."
False," The study does not meet the inclusion criteria because it is a preliminary study and does not meet the inclusion criteria for study design (randomized controlled trials, good quality systematic reviews, and comparative observational studies)."
False," The study focuses on the design of pharmacoeconomic evaluations and the need for long-term, randomized field trials, but it does not discuss the effectiveness or harms of a specific medication in a patient population."
False," The study population is children with autism, which does not match the specified inclusion criteria of children (under age 13 years) and adolescents (age 13-17 years) with a pervasive developmental disorder, including autistic disorder."
False," The study is not related to the inclusion criteria as it is about mechanical lesions of the fimbria fornix in rat brain, not about schizophrenia, bipolar disorder, or other psychiatric conditions."
False," The study population does not match the inclusion criteria, as it specifically includes patients with Parkinson's disease, whereas the review is focused on patients with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions."
False," The study does not match the inclusion criteria because it does not focus on the effectiveness or harms of clozapine in the specified patient populations, but rather on the incidence of neutropenia and agranulocytosis in patients receiving clozapine."
False," The study population does not match the specified inclusion criteria as it only includes schizophrenic patients undergoing clozapine treatment, whereas the review includes various patient populations with different diagnoses and treatment interventions."
False," The article does not meet the inclusion criteria as it is a single study examining the effects of a clozapine national registry system on incidence of deaths related to agranulocytosis, whereas the review is focused on a broader range of antipsychotics and outcomes."
True," The study meets all inclusion criteria, including being a randomized controlled trial, examining the effectiveness of risperidone in patients with schizophrenia, and measuring outcomes such as symptom response and adherence."
False," The study is not a randomized controlled trial or a systematic review, and it does not examine the relationship between improved adherence or persistence and improved outcomes."
True," The study meets all the inclusion criteria as it is a randomized, double-blind trial comparing an atypical antipsychotic (zotepine) to a typical antipsychotic (haloperidol) in patients with acute exacerbation of schizophrenia, and reports on effectiveness and harm outcomes."
False," The study population is patients with schizophrenia, but the intervention being compared is olanzapine to placebo, which is not one of the included interventions."
False," The study population includes adults with schizophrenia, bipolar disorder, and major depressive disorder, but also includes children with pervasive developmental disorders and disruptive behavior disorders, which is outside the specified age range."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of glycine as an adjunctive therapy for treatment-resistant schizophrenia, which is a relevant population for the review."
False," The study does not meet the inclusion criteria because it does not involve a diagnosis of schizophrenia, bipolar disorder, major depressive disorder, or other disorders specified in the inclusion criteria."
True," The study meets the inclusion criteria as it involves adults with a diagnosis of schizophrenia, bipolar disorder, or major depressive disorder, and it examines the effectiveness of olanzapine, which is an intervention included in the review."
True," The study meets all inclusion criteria, including the population (adults with schizophrenia), intervention (olanzapine), and outcome (efficacy and safety) criteria."
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness of the specified interventions (e.g., aripiprazole, asenapine, clozapine) in the specified patient populations, and it does not report on the specified outcomes (e.g., mortality, quality of life, functional capacity)."
False," The study population does not match the specified criteria, as it only includes patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, whereas the review includes patients with pervasive developmental disorders, disruptive behavior disorders, and other diagnoses."
False," The study does not meet the inclusion criteria for the review, as it is not a randomized controlled trial, systematic review, or comparative observational study examining the effectiveness or harms of the specified interventions in the specified patient populations."
True," The study meets all the inclusion criteria, including the population (adults with treatment-refractory schizophrenia), interventions (clozapine), outcomes (therapeutic response, side effects), and study design (randomized controlled trial)."
False," The study does not meet the inclusion criteria because it is a single study examining the effectiveness of fluoxetine augmentation of clozapine treatment in patients with schizophrenia, whereas the review is looking for randomized controlled trials, good-quality systematic reviews, and comparative observational studies examining the effectiveness of various interventions for a range of psychiatric conditions."
False," The study population does not match the inclusion criteria, as it only includes adults with schizophrenia receiving clozapine."
False," The study population is children with early-onset schizophrenia, which is outside the specified age range of 13-17 years."
True," The study meets all inclusion criteria, including a focus on the effects of quetiapine on platelet serotonin-2 binding in schizophrenia, a relevant population (adults with schizophrenia), and a study design (randomized controlled trial) that is included in the review."
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the efficacy and safety of risperidone with haloperidol in patients with chronic schizophrenia, which is within the scope of the review."
True," The study meets all inclusion criteria, including the population of interest (schizophrenic patients with a history of treatment resistance to clozapine), the intervention (adjunctive loxapine), and the study design (open clinical trial)."
False," The article does not meet the inclusion criteria as it is about polypharmacy in bipolar I disorder, which is not one of the specified conditions (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, or disruptive behavior disorders) and the interventions and outcomes mentioned do not match the specified criteria."
False," The study population in this paper does not match the inclusion criteria, as it specifically focuses on patients with obsessive-compulsive disorder (OCD), whereas the review paper includes patients with schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of clozapine in patients with schizophrenia, and it reports on outcomes such as hospitalization, symptom response, and quality of life, which are relevant to the review."
False," The study population does not match the inclusion criteria as it specifically focuses on patients with schizophrenia and bipolar disorder, whereas the inclusion criteria include a broader range of diagnoses such as pervasive developmental disorders, disruptive behavior disorders, and behavioral and psychological symptoms of dementia."
True," The study meets the inclusion criteria as it investigates the incidence and time course of clozapine-induced weight gain, which is a relevant outcome for the review, and includes a comparison with standard antipsychotics."
True," The study meets the inclusion criteria as it involves a randomized controlled trial (RCT) examining the effectiveness of clozapine in treatment-refractory patients with schizophrenia, which is a population of interest for the review."
False," The study population specified in the abstract (schizophrenic patients) does not match the inclusion criteria (patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia)."
False," The study population does not match the specified inclusion criteria, as the study only includes patients taking clozapine and haloperidol, whereas the review is focused on patients with various psychiatric disorders and those taking specific antipsychotic medications."
False," The study population does not match the specified criteria, as it only includes Chinese acutely exacerbated schizophrenic inpatients, whereas the review includes adults and adolescents with various psychiatric disorders."
True, The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of a neural network based on adaptive resonance theory (ART) to expert opinions in suggesting treatment for schizophrenic and unipolar depressed inpatients.
True," The article meets the inclusion criteria of the review, including the population of interest (adults and adolescents with schizophrenia and other psychotic disorders), the interventions (olanzapine), and the outcomes (efficacy and safety)."
True, The study meets the inclusion criteria as it is a randomized controlled trial investigating the effectiveness of olanzapine in treating negative symptoms of schizophrenia.
True," The study meets all the inclusion criteria as it is a meta-analysis of randomized controlled trials examining the effectiveness and side effects of risperidone in the treatment of schizophrenia, which is one of the interventions included in the review."
False," The study population of the paper does not match the inclusion criteria, as the participants are adults with schizophrenia, but the review is focused on children and adolescents with pervasive developmental disorders and disruptive behavior disorders."
False," The study is a case series, not a randomized controlled trial, comparative observational study, or systematic review, which are the types of studies included in the review."
True,"<This study meets the inclusion criteria as it examines the effectiveness of clozapine in patients with schizophrenia, a population of interest, and reports on symptom response, which is an effectiveness outcome of interest.>"
False, The study population is not one of the specified populations (Parkinson's disease patients with tremor) and the intervention (clozapine and benztropine) is not one of the specified interventions (atypical antipsychotics).
False," the study population is not adults with treatment-resistant schizophrenia, but rather specifically ten patients with treatment-resistant schizophrenia."
False," The study population is children with autistic disorder, but the review only includes studies on children under 13 years old with a DSM-III-R or DSM-IV diagnosis of a pervasive developmental disorder, including autistic disorder, Asperger’s disorder, pervasive developmental disorder not otherwise specified (including atypical autism)."
True," The study meets all the inclusion criteria, as it is a retrospective analysis of patients with schizophrenia, examines the association between substance abuse and tardive dyskinesia, and uses a robust statistical analysis (ANOVA)."
True," The study meets the inclusion criteria as it involves a head-to-head comparison of two antipsychotic medications (risperidone and haloperidol) in antipsychotic-naive schizophrenic patients, and it examines the adverse effects of risperidone on eye movement activity."
False," The article does not meet the inclusion criteria because it does not focus on the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, and dementia) and interventions (antipsychotic medications)."
False, The study population does not match the inclusion criteria as it focuses on nursing home research from the industry's perspective and does not specifically target the populations mentioned in the inclusion criteria.
True," The article meets all the inclusion criteria, including the population (adults and adolescents with schizophrenia and related psychoses), interventions (novel antipsychotic drugs), outcomes (effectiveness and harms), and study designs (randomized controlled trials, systematic reviews, and observational studies)."
False," The study does not investigate the effectiveness or harms of risperidone, but rather compares the bioavailability of two different formulations of the medication."
True," The study meets all the inclusion criteria, including the population (young paranoid schizophrenic patients), intervention (investigation of relationship between cognitive and coping characteristics and stressful life events), comparison (relapse vs. no relapse), and outcome (P300 measures, subjective complaints, and coping capacity)."
True," This article meets all the inclusion criteria, as it is a randomized, double-blind comparison of treatment with risperidone and haloperidol in treatment-resistant schizophrenic patients, and it assesses the effect of risperidone on verbal working memory."
True," The study meets all the inclusion criteria, including a randomized controlled trial design, a focus on adults with schizophrenia, and a comparison of olanzapine with haloperidol."
True," The study meets all the inclusion criteria, including the population (adults with schizophrenia), interventions (risperidone), and outcomes (extrapyramidal symptoms) of interest."
False," The abstract does not mention any of the inclusion criteria, such as specific patient populations, interventions, or outcomes."
False," The study population is adults with depression in the community, which does not match the inclusion criteria of adults (age 18 years and older) with schizophrenia, bipolar disorder, major depressive disorder, or other specific conditions."
True, The study meets all the inclusion criteria as it is a head-to-head randomized controlled trial comparing the extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
False," The study population does not match the inclusion criteria as it only includes adults with schizophrenia, whereas the review includes children, adolescents, and adults with various psychiatric conditions."
False," The study does not meet the inclusion criteria for interventions, as it involves a selective D4 dopamine receptor antagonist (L-745,870), which is not one of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone)."
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (e.g. aripiprazole, clozapine, etc.) and does not examine the effectiveness outcomes specified (e.g. mortality, quality of life, etc.)."
False,"<The article does not discuss the effects of psychotropic drugs on pathologic aggression in the specified populations, but rather reviews the treatment of pathologic aggression in general.>"
False," The study population does not match the inclusion criteria, as it specifically focuses on patients with Parkinson's disease, whereas the review paper includes patients with schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
False," The study population and interventions mentioned in the abstract do not match the specified inclusion criteria, as the study focuses on pregnancy risks of psychotropic agents, not the specified patient populations and interventions."
False," The study population does not match the inclusion criteria, as it only includes adults with schizophrenia, whereas the review includes a broader range of populations, including bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
True," The study meets the inclusion criteria as it compares the efficacy of clozapine with chlorpromazine in the treatment of acute mania, and the population of interest (adults with bipolar disorder) matches the inclusion criteria."
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia, whereas the review includes a broader range of populations such as bipolar disorder, major depressive disorder, and dementia."
True," The study meets the inclusion criteria as it focuses on adults with schizophrenia, uses utility analysis to assess economic and quality-of-life benefits of risperidone, and presents results in a format that can be compared to other studies included in the review."
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified interventions in the specified patient populations, and it is not a randomized controlled trial, good-quality systematic review, or comparative observational study."
False," The article's focus is on antipsychotic use in pregnancy, which does not match the inclusion criteria of the review, which focuses on adults and adolescents with various psychiatric conditions."
True," The study meets all inclusion criteria, including a randomized controlled trial design, a comparison of clozapine and chlorpromazine, and outcomes relevant to the review (efficacy, adverse effects, and withdrawals due to adverse events)."
False," The study does not meet the inclusion criteria as it is a preliminary study examining the therapeutic efficacy of methylene blue in schizophrenia, but it is not a randomized controlled trial, a good-quality systematic review, or a comparative observational study."
False," The study does not examine the effectiveness of one of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone) in the specified patient population (schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia)."
False," The study does not meet the inclusion criteria as it is a case-control study examining the association between a genetic polymorphism and schizophrenia, rather than evaluating the effectiveness or harms of a specific medication."
False, The study population (adults with schizophrenia) does not match the inclusion criteria (children and adolescents with pervasive developmental disorders and disruptive behavior disorders).
False," The study population does not match the specified population for this review, as the study only includes patients with acute exacerbation of chronic schizophrenia, which is not one of the specified populations."
True," The study meets all the inclusion criteria as it is a longitudinal investigation of plasma G-CSF levels in schizophrenic patients during clozapine treatment, which is one of the interventions included in the review."
False," The study is not a randomized controlled trial, but rather a case report and a suggestion for future study, and it does not address the specified effectiveness outcomes or inclusion criteria."
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of clozapine in treatment-refractory patients with schizophrenia, which is a relevant intervention for the review."
True," The article meets all the inclusion criteria, including the population (adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia), interventions (olanzapine), and outcomes (incidence of tardive dyskinesia)."
True," The study meets all inclusion criteria, including the diagnosis of refractory schizophrenia, the comparison of clozapine and haloperidol, and the evaluation of effectiveness outcomes such as symptom response, hospitalization, and quality of life."
True," The study meets all the inclusion criteria, including the population (adults with schizophrenia), interventions (olanzapine and risperidone), and outcomes (efficacy and safety)."
True," The study meets all the inclusion criteria as it focuses on the effects of Risperidone on polydipsia in chronic schizophrenia patients, which is a relevant population for the review, and the study design (randomized controlled trial) is also included in the criteria."
False," The population of interest in the study is adults, adolescents, and children with various psychiatric conditions, but the study focuses on the safety assessment of risperidone, not its effectiveness."
False," The study's population is limited to adults and adolescents with schizophrenia, whereas the review includes studies on patients with various psychiatric conditions, including bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
True," The study meets all inclusion criteria, as it involves a relevant population (schizophrenic patients), intervention (clozapine), and outcome (blunting of ketamine-induced psychotic symptoms), and was conducted using a randomized controlled trial design."
True, The study meets all inclusion criteria as it is a randomized controlled trial examining the effectiveness of two atypical antipsychotics (clozapine and risperidone) in patients with schizophrenia.
False," The abstract does not mention any of the specified psychiatric conditions or medications, and the study appears to be investigating the effects of dioxin exposure on cancer mortality, which is not relevant to the review's focus on psychiatric treatments and outcomes."
False," The study population of 14 inpatients with schizophrenia or schizoaffective disorder does not match the inclusion criteria of adults (age 18 years and older) with a DSM III-R or DSM-IV diagnosis of schizophrenia, including other psychotic disorders."
False," The study population is not limited to adults (18 years and older) and adolescents (13-17 years) with schizophrenia, but also includes patients with other conditions such as bipolar disorder and behavioral and psychological symptoms of dementia."
False," The study does not examine the effectiveness or harms of the interventions in the specified patient populations, but rather the feasibility of starting a new psychopharmacologic intervention before discharge."
True," The study meets the inclusion criteria as it involves patients with psychoses, assesses the efficacy of loxapine, and uses a randomized controlled trial design."
False," The study population does not match the inclusion criteria, as it only includes elderly patients with agitation and neuropsychiatric disorders, whereas the review includes a broader range of populations such as schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia in older adults, among others."
False,"The study population does not match the inclusion criteria as it focuses on adults and adolescents with schizophrenia, bipolar disorder, and other conditions, whereas the review is focused on children (under 13 years) and adolescents (age 13-17 years) with pervasive developmental disorders and disruptive behavior disorders."
False," The study population does not match the specified inclusion criteria, as the study focuses on patients with rapid-cycling bipolar disorder, whereas the review paper is focused on a broader range of psychiatric disorders, including schizophrenia, bipolar disorder, and major depressive disorder."
False," The title and abstract indicate that the article focuses on the use of clozapine in nonschizophrenic patients, whereas the inclusion criteria specify that the review focuses on schizophrenia and other specific disorders."
True," The study meets the inclusion criteria as it is a review of the pharmacology, pharmacokinetics, efficacy, and adverse effects of olanzapine, and it includes data from randomized controlled trials and observational studies in patients with schizophrenia."
True, The study meets the inclusion criteria as it involves adults with a DSM-III-R diagnosis of schizophrenia and examines the efficacy of olanzapine in the maintenance treatment of schizophrenia.
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of olanzapine, and the measurement of clinical response and plasma concentrations."
True," The study meets all the inclusion criteria, including the population (patients with schizophrenia), interventions (olanzapine, haloperidol, and placebo), outcomes (quality of life and efficacy), and study design (randomized controlled trial)."
True," The study meets all inclusion criteria, including the population of interest (Spanish schizophrenic patients), the intervention (olanzapine vs. haloperidol), and the study design (cost-effectiveness analysis using a clinical decision model)."
False," The title and abstract do not match the inclusion criteria, as the study is comparing risperidone and haloperidol in patients with schizophrenia, but the inclusion criteria specify a review of multiple antipsychotics and patient populations."
False," The study population (withdrawn cocaine-dependent patients) does not match the specified inclusion criteria (schizophrenia, bipolar disorder, major depressive disorder, etc.)."
False," The article is a letter to the editor in response to criticisms of a previous study, and does not report on a randomized controlled trial or other study design that meets the inclusion criteria."
False," The article's title and abstract do not suggest that the study is focused on childhood-onset schizophrenia, and the text is actually a description of a review paper's inclusion and exclusion criteria, not a study abstract."
False," The paper does not meet the inclusion criteria as it does not focus on the effects of selective serotonin reuptake inhibitors (SSRIs) on CNS drug interactions, but rather on the interactions themselves."
False," The study population does not match the inclusion criteria, as it specifically focuses on elderly schizophrenic patients with or without tardive dyskinesia, which is not mentioned in the inclusion criteria."
False," The study population does not match the specified inclusion criteria as it only includes patients with treatment-resistant schizophrenia, whereas the review paper includes a broader range of populations such as patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The study population does not match the specified inclusion criteria, as it only includes patients with treatment-resistant schizophrenia, whereas the review is focused on a broader range of psychiatric conditions."
True," The study meets all inclusion criteria, as it involves adults with schizophrenia, uses a randomized controlled trial design, and examines the effectiveness of risperidone compared to haloperidol."
False," The study does not meet the inclusion criteria for the review as it is a retrospective, descriptive study with a small sample size and does not include a comparison group, and it does not examine the relationship between improved adherence or persistence and improved outcomes."
True," The study meets all inclusion criteria, including the population (schizophrenia patients), interventions (neuroleptic drugs), outcomes (relapse rates, quality of life), and study design (randomized controlled trials)."
False," The article does not focus on adults (age 18 years and older) with schizophrenia, including first episode schizophrenia or patients refractory to treatment, which is a key inclusion criterion."
False," The article does not meet the inclusion criteria as it does not involve any of the specified interventions (e.g. aripiprazole, asenapine, etc.) or patient populations (e.g. schizophrenia, bipolar disorder, etc.)."
False," The study population does not match the inclusion criteria, as it only includes healthy male volunteers, whereas the review paper is focused on patients with various psychiatric disorders."
False, The article does not meet the inclusion criteria as it is a general introduction to atypical antipsychotics and does not discuss the effectiveness or harms of sertindole specifically.
False," The study does not meet the inclusion criteria for interventions, as it specifically investigates the pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors, but does not involve the other included interventions (e.g. aripiprazole, asenapine, iloperidone, etc.)."
False," The study population specified in the title and abstract (patients with bipolar disorder) does not match the inclusion criteria specified in the review (adults with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, among others)."
False," The study population does not match the inclusion criteria, as the study only examines patients with schizophrenia and does not include other psychiatric disorders such as bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
True," The article meets all the inclusion criteria, including the focus on schizophrenia treatment recommendations, the population of interest (adults and adolescents with schizophrenia), the type of study (systematic review of treatment outcomes), and the outcomes of interest (effectiveness and harms of various interventions)."
False,"<The article does not meet the inclusion criteria because it is a survey study examining conformance of usual care to treatment recommendations, rather than a randomized controlled trial, systematic review, or comparative observational study examining the effectiveness of interventions for the specified conditions.>"
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia in adolescents, the use of clozapine as an intervention, and the evaluation of effectiveness outcomes such as symptom response and adherence."
False, The study does not meet the inclusion criteria because it is an interaction study with imipramine and does not involve the use of the medications listed in the inclusion criteria.
False, The article does not meet the inclusion criteria because it is a general overview of atypical antipsychotics and does not discuss the effectiveness or harms of specific medications in the specified patient populations.
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial design, and examines the effectiveness of olanzapine compared to haloperidol on depressive symptoms."
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms.
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial design, and evaluates the effectiveness of sulpiride augmentation in patients partially responsive to clozapine."
False," The study population specified in the title and abstract (patients with chronic schizophrenia) does not match the specified inclusion criteria (adults with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, as well as children and adolescents with pervasive developmental disorders and disruptive behavior disorders)."
False," The study only compares risperidone and haloperidol, whereas the review is interested in a broader range of antipsychotic medications."
True,"<This study meets the inclusion criteria as it is a randomized controlled trial comparing the effectiveness of clozapine and risperidone in treatment-resistant schizophrenia, and reports on relevant outcomes such as symptom response and quality of life.>"
True," The study population includes schizophrenic patients, which matches the inclusion criteria, and the study investigates the correlation between plasma clozapine concentration and heart rate variability, which is a relevant outcome for the review."
True," The study meets all the inclusion criteria, including the population of interest (patients with treatment-resistant chronic schizophrenia), interventions (risperidone and clozapine), and outcomes (efficacy and safety)."
True," The study meets all inclusion criteria, including the population (schizophrenic patients), interventions (chlorpromazine, clozapine, and amisulpride), and outcomes (5-HT2A receptor blockade), and is a randomized controlled trial."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness and safety of risperidone in patients with schizophrenia, which is a relevant population for this review."
False,"<The article does not meet the inclusion criteria as it is a head-to-head trial comparing risperidone with a combination of haloperidol and amitriptyline, but it does not include any of the specified interventions (e.g. aripiprazole, clozapine, etc.) or patient populations (e.g. schizophrenia, bipolar disorder, etc.).>"
False," The article appears to be a commentary on another study, rather than an original research article."
False, The article is a commentary on another study and does not report original research or data.
True," The study meets the inclusion criteria for the population (schizophrenia patients), interventions (sertindole and haloperidol), and outcomes (efficacy and safety)."
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the efficacy and safety of haloperidol and olanzapine in patients with schizophrenia, and examines the relationship between extrapyramidal side effects and negative symptoms."
False," The study focuses on the clinical outcome predictors and cost-effectiveness of risperidone in a naturalistic setting, which does not match the specified inclusion criteria of randomized controlled effectiveness trials, good quality systematic reviews, and comparative observational studies examining specific patient populations and outcomes."
False," The study does not meet the inclusion criteria as it focuses on the effects of clozapine on EEG photic driving in patients with schizophrenia, whereas the review is interested in the effectiveness and harms of various antipsychotic medications in different patient populations."
False," The study does not meet the inclusion criteria for patient population, as it only includes adults with schizophrenia, whereas the review is focused on a broader range of patient populations, including children and adolescents with various diagnoses."
False, The article does not meet the inclusion criteria as it does not mention any specific interventions or outcomes related to the treatment of schizophrenia or other psychiatric disorders.
True," The study meets all the inclusion criteria, including the population (patients with schizophrenia and/or schizoaffective disorders), intervention (clozapine), and outcomes (hospital utilization and cost savings)."
False," The study population of patients with treatment-resistant bipolar disorder does not match the specified inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
True," The study meets all inclusion criteria, including a randomized controlled trial design, a focus on schizophrenia, and an evaluation of the effectiveness of olanzapine compared to haloperidol and placebo."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the efficacy of risperidone in the treatment of mania, a condition included in the review, and it reports on relevant outcomes such as symptom response and adverse effects."
True," The study meets all the inclusion criteria, including a randomized controlled trial design, a focus on schizophrenia, and examination of the effectiveness of clozapine."
False," The study does not meet the inclusion criteria because it focuses on anticonvulsants in treating agitated demented elderly patients, which is not a population or diagnosis specified in the inclusion criteria."
False," The paper is not a randomized controlled trial, systematic review, or comparative observational study, which are the only study designs included in the review."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of risperidone as an intervention, and the inclusion of effectiveness outcomes such as symptom response and adherence."
False," The study does not examine the effectiveness or harms of clozapine, but rather its pharmacokinetic interaction with itraconazole."
False, The study is an in vitro study and does not meet the inclusion criteria of being a randomized controlled trial or a comparative observational study examining the relationship between improved adherence or persistence and improved outcomes.
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of clozapine as an intervention, and the examination of the relationship between genetic polymorphisms and treatment response."
False," The study does not meet the inclusion criteria as it does not involve interventions included in this review (e.g. aripiprazole, asenapine, etc.) and does not examine effectiveness outcomes included in this review (e.g. mortality, quality of life, etc.)."
False," The study does not meet the inclusion criteria as it does not examine the effectiveness of olanzapine in patients with schizophrenia, but rather compares it to chlorpromazine in patients who have failed to respond to haloperidol."
True,"<The study meets all the inclusion criteria, as it is a randomized controlled trial examining the effectiveness and harms of olanzapine in patients with schizophrenia, and it reports on outcomes such as efficacy, adherence, and adverse effects, which are of interest for this review.>"
False," The study population is not specified as adults or adolescents with schizophrenia, bipolar disorder, or other specified conditions, and the study design is a naturalistic study, not a randomized controlled trial."
False," The study population does not match the specified inclusion criteria, as it only includes patients treated with clozapine or conventional depot neuroleptics, but does not include patients with schizophrenia, bipolar disorder, or other specified conditions."
True," The study meets all the inclusion criteria, including the population (patients with refractory schizophrenia), intervention (clozapine), and outcomes (quality of life, symptom outcomes) of interest."
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of risperidone in adults with autistic disorder and other pervasive developmental disorders.
False," The study does not focus on individuals with autism, but rather on individuals with various psychiatric conditions, including schizophrenia, bipolar disorder, and dementia."
True, The study meets the inclusion criteria as it is a randomized controlled trial comparing the effects of risperidone and haloperidol on emotion perception in treatment-resistant schizophrenia patients.
False," The article does not meet the inclusion criteria because it is not a randomized controlled trial, systematic review, or observational study examining the effectiveness or harms of quetiapine in the specified patient populations."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia or schizoaffective disorder, the use of ziprasidone as an intervention, and the inclusion of effectiveness outcomes such as symptom response and hospitalization."
False," The article is about olanzapine-induced reversible priapism, but the inclusion criteria specify that the review paper is focused on the effectiveness and harms of various antipsychotic medications in various patient populations."
True," The study meets all inclusion criteria, including the population of interest (patients with chronic schizophrenia), the intervention (risperidone), and the study design (open-label, multicentre study)."
False," The study population consists of individuals with schizophrenia treated with clozapine or typical neuroleptics, which does not match the specified inclusion criteria of adults with bipolar disorder, major depressive disorder, and other conditions."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of amisulpride as an intervention, and the inclusion of effectiveness outcomes such as symptom response and adverse effects."
True," The study meets all inclusion criteria, including the population of interest (adults and adolescents with schizophrenia and other psychotic disorders), interventions (olanzapine), and outcomes (effectiveness and harms)."
True," The study meets all the inclusion criteria, including the diagnosis of schizophrenia, the use of clozapine as an atypical antipsychotic agent, and the examination of effectiveness outcomes such as impulsiveness, aggressiveness, and suicidality."
False," The study population does not match the specified inclusion criteria, as the participants are limited to normal control subjects and schizophrenic patients, whereas the review includes a broader range of psychiatric populations."
True," The study meets all the inclusion criteria, including the population of interest (patients with schizophrenia and schizoaffective disorder), the intervention (clozapine therapy), and the outcome (suicide prevention)."
False," The study population does not match the inclusion criteria, as it only includes patients with genetic variation in 5-HT2A receptors, whereas the review includes a broader range of patient populations."
False," The study population only includes adults and adolescents with schizophrenia, which does not match the inclusion criteria of the review, which includes children and adolescents with various psychiatric disorders."
False," The study does not meet the inclusion criteria as it does not involve humans (adults, adolescents, or children) with a diagnosis of schizophrenia or other psychiatric disorders, and it does not examine the effectiveness or harms of the specified interventions in these populations."
False," The study does not meet the inclusion criteria because it does not focus on the effectiveness or harms of the interventions listed in the inclusion criteria, but rather on the pharmacokinetics of clozapine and its metabolite CNO."
False," The study focuses on adults and adolescents with schizophrenia, but does not specifically mention the age range of 18-25 years, which is the target population of interest for this review."
False," The study population is nursing home patients, which does not match the specified inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The paper does not mention bipolar illness as the primary focus, but rather as one of several disorders discussed in the context of treatment approaches."
True," The study meets the inclusion criteria as it is a randomized clinical trial comparing clozapine and haloperidol in patients with refractory schizophrenia, which is the population of interest, and examines outcomes such as symptom response, quality of life, and hospitalization."
False," The study population does not match the inclusion criteria, as the study focuses on treatment-refractory patients with schizophrenia, whereas the review includes patients with a range of psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia."
False," The study does not examine the relationship between improved adherence or persistence and improved outcomes, which is a key outcome of interest in the review."
False," The study population of the paper does not match the inclusion criteria, as it only includes patients with bipolar disorder, whereas the review includes patients with schizophrenia, bipolar disorder, major depressive disorder, and other conditions."
True," The study investigates the effects of clozapine treatment on cognitive event-related potentials in patients with schizophrenia, which is a relevant population for the review."
True," The study meets all inclusion criteria, including the population (treatment-resistant schizophrenia patients), interventions (risperidone vs. haloperidol), and study design (randomized, double-blind comparison)."
True," The study examines the relationship between patient variables and plasma clozapine concentrations, which is a relevant topic for the review paper."
True," The study meets all the inclusion criteria, including the population (adults with schizophrenia), interventions (risperidone and traditional antipsychotics), and outcomes (economic outcomes, including total cost of care)."
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of risperidone in patients with schizophrenia, which is a condition included in the review."
True," The study meets all the inclusion criteria, including a diagnosis of schizophrenia, use of clozapine or risperidone as interventions, and assessment of effectiveness outcomes such as symptom response and adverse effects."
False," The study population (older adults with behavioral and psychological symptoms of dementia) does not match the inclusion criteria, which specify adults (18+ years) and adolescents (13-17 years) with schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders, among others."
False," The study population does not match the specified inclusion criteria, as it only includes adults with schizophrenia treated with clozapine, whereas the review includes a broader range of populations and interventions."
False," The study being reviewed is about post-marketing surveillance of newly marketed drugs, whereas the review is focused on the effectiveness and harms of specific antipsychotic medications for various psychiatric conditions."
False," The study only compares olanzapine and haloperidol, and does not include other antipsychotics listed in the inclusion criteria."
False," The study population is not specified as adults (18 years and older) or adolescents (13-17 years) with a DSM III-R or DSM-IV diagnosis of schizophrenia, but rather a specific geographic population with schizophrenia in Scotland."
True," The study includes adults with recent-onset schizophrenia, which matches the inclusion criteria, and it examines the effects of risperidone on P50 suppression, which is relevant to the review's focus on interventions for schizophrenia."
False," The study population is inpatients with schizophrenia, including schizodominant schizoaffective disorder, which does not match the specified patient populations of interest (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders)."
False," The study population does not match the inclusion criteria, as the study only includes Taiwanese schizophrenic patients, whereas the review includes a broader range of patient populations."
False," The study population is not limited to adults (age 18 years and older) with schizophrenia, bipolar disorder, or major depressive disorder, as the study includes adolescents (13-17 years) and children (under 13 years) with various diagnoses, including pervasive developmental disorders and disruptive behavior disorders."
False, The title does not clearly indicate the focus on medication effectiveness for various psychiatric disorders.
False, The study does not meet the inclusion criteria as it is a pharmacokinetic study in healthy men and does not involve the treatment of any psychiatric disorder or condition.
False," The article does not focus on the pharmacokinetics of psychotropic drugs, but rather reviews the clinical significance of pharmacokinetic drug interactions in psychopharmacology."
True," The study meets all the inclusion criteria, as it is a randomized controlled trial examining the effectiveness and safety of ziprasidone in patients with schizophrenia and schizoaffective disorder, which are included populations in the review."
True, The study meets all the inclusion criteria as it involves a pharmacokinetic interaction between two medications (carbamazepine and olanzapine) that are likely to be used concomitantly in the treatment of manic psychotic disorder.
False," The abstract does not mention the specific population of interest (adults with schizophrenia) and focuses on the pharmacological management of schizophrenia in general, and the comparison of risperidone and olanzapine."
False,"<The study population does not match the inclusion criteria, as it includes children under 13 years with pervasive developmental disorders, which is not specified in the inclusion criteria for children under 13 years.>"
False," The study is an open trial, not a randomized controlled trial, which is excluded from the criteria."
True," The study meets the inclusion criteria as it involves adults with refractory schizophrenia, a randomized controlled trial, and examines the effectiveness of clozapine compared to haloperidol."
False," The study population does not match the inclusion criteria, as the study only includes healthy human volunteers, not individuals with schizophrenia or other psychotic disorders."
False,"<The article is about the general mechanism of antipsychotics, their classification, and their side effects, but it does not specifically address the effectiveness of antipsychotics in treating adults with schizophrenia, which is the focus of the review.>"
False," The study population does not match the specified criteria, as it only includes schizophrenic patients treated with clozapine, fluphenazine, or placebo, whereas the review focuses on a broader range of psychiatric conditions and medications."
False,"<The article is a letter to the editor commenting on another study, rather than a primary research study, and does not report on the effectiveness of clozapine in the specified patient populations or outcomes.>"
True," The study meets all the inclusion criteria, including the population (first-episode psychosis), interventions (olanzapine and haloperidol), and outcomes (efficacy and safety)."
False," The study population includes patients with refractory schizophrenia, which is within the specified age range, but the study focuses on the effect of clozapine on negative symptoms and the deficit syndrome, which is not a primary outcome of interest for this review."
False," The study population does not match the specified population of interest, as it only includes adults with treatment-resistant schizophrenia, whereas the review includes various age groups and diagnoses."
True," The study meets all inclusion criteria, including the diagnosis of schizophrenia and the use of risperidone or olanzapine as interventions, and the outcomes of interest such as treatment response and side effects are also relevant to this review."
False," The study population does not match the inclusion criteria, as it specifically targets patients with HIV-associated psychosis and drug-induced parkinsonism, whereas the review is focused on a broader range of psychiatric conditions and populations."
False," The study does not focus on the specified age group of ""older adults (≥ 65 years of age) with behavioral and psychological symptoms of dementia"" but rather includes elderly patients in general, making it not a good fit for the review."
False," The article's focus is on atypical neuroleptics in children and adolescents, but it does not meet the inclusion criteria for adults (age 18 years and older) with a DSM III-R or DSM-IV diagnosis of schizophrenia, bipolar disorder, or major depressive disorder, which are specified in the inclusion criteria."
False," The study does not meet the inclusion criteria as it is a review of the necessity of placebo-controlled studies in schizophrenia, not a study examining the effectiveness of a specific medication or intervention in patients with schizophrenia or other disorders."
True," The study meets all inclusion criteria, including the population (patients with schizophrenia), intervention (combination treatment with clozapine and paroxetine), and outcomes (safety and tolerability data)."
True," The study meets all the inclusion criteria, including the population (adults and adolescents with schizophrenia), the intervention (risperidone), and the outcomes (adverse events and plasma prolactin levels)."
False," The study population does not match the specified criteria for schizophrenia, as it only mentions co-existence of OCD with schizophrenia, but does not explicitly state that the participants have schizophrenia."
False," The study population specified in the inclusion criteria does not match the study population in the abstract, which focuses on adults and adolescents with schizophrenia, bipolar disorder, and other psychotic disorders, whereas the inclusion criteria specify a broader range of populations, including children, older adults, and individuals with pervasive developmental disorders and disruptive behavior disorders."
True," the study meets the inclusion criteria for adults (age 18 years and older) with a DSM III-R or DSM-IV diagnosis of schizophrenia, including other psychotic disorders such as schizophreniform, delusional, and schizoaffective disorders, and including first episode schizophrenia or patients refractory to treatment."
False," The study population consists of psychiatric inpatients who received antipsychotic drugs, which does not match the specified inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia."
